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 This cross-sectional study evaluated body composition via a four-compartment model, 
muscle characteristics, cardiometabolic blood markers, resting and exercise metabolism, and 
lifestyle factors (physical activity, sleep quality, diet, and number of menopause symptoms) 
in 24 pre-menopausal (PRE), 24 peri-menopausal (PERI), and 24 post-menopausal (POST) 
women. Significant differences (p<0.05) were reported for body fat percent (%fat), android 
to gynoid ratio (AG ratio), rate of fat oxidation during moderate intensity exercise, and 
number of menopause symptoms. PERI women experienced the highest %fat, the greatest 
central obesity, reduced metabolic flexibility, and the greatest number of menopause 
symptoms. Muscle quality was lowest in PERI and remained low in POST, while markers of 
cholesterol increased through the menopause transition. Peri-menopause may be the most 
opportune window for lifestyle intervention, as this group experienced unfavorable body 
composition and metabolism compared to the other groups despite similarities in body mass 
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CHAPTER I: INTRODUCTION 
Women spend up to 40% of their lives in the post-menopausal stage1.Women are living 
longer and spending substantially more time in the post-menopause stage, which is associated 
with increased risk of cardiovascular disease (CVD), insulin resistance, and osteoporosis2–6. 
Menopause is an inevitable female transition through which the production of ovarian hormones 
(estrogen and progesterone) dramatically decreases, resulting in a loss of reproductive 
capabilities7. Menopause is linked to increased disease risk due to harmful changes in body 
composition including increased fat mass (FM), decreased lean mass (LM), and decreased bone 
mineral density (BMD), which cumulatively are incited largely by the reduction of estrogen and 
summarized in Figure 1. Despite the prevalence and physiological impact of menopause, little is 
known about its influence on metabolism, specifically resting energy expenditure (REE), or 
muscle characteristics (i.e., muscle size and quality). Exercise may be a key mitigating factor for 
reducing disease risk related to menopause. However, the relationship between metabolic 
attributes, body composition, lifestyle factors, and exercise capacity has not been fully elucidated 
throughout menopause. 
Estrogen is regarded as a master regulator of bioenergetic systems in the female body8, so 
it is unsurprising that the drop in circulating estradiol associated with the menopause transition 
affects both metabolism and body composition. Specifically, estrogen is a key regulator of 
adiposity, insulin kinetics, and energy expenditure9. It is well-known that energy expenditure                                                                                                                             




as an independent factor that may influence REE and substrate utilization during exercise 
(i.e., metabolic flexibility). In existing literature, it is evident that menopause reduces total 
energy expenditure (TEE), but the effects of menopause on REE are inconclusive11,12. An overall 
reduction in energy expenditure complicates energy balance and may exacerbate changes in body 
composition and fat redistribution, concurrently tied to the decrease in estrogen. Post-
menopausal status is associated with a 60% increased risk of metabolic syndrome (MetS), even 
after adjusting for confounding factors4. MetS is characterized by increased visceral adipose 
tissue (VAT), elevated total cholesterol (TC), reduced high-density lipoprotein (HDL), and 
elevated low-density lipoprotein (LDL)13. These unfavorable metabolic phenotypes are likely 
interconnected to the elevated risk of CVD and associated with changes in body composition 
during and after the menopause transition.  
In the years preceding menopause known as “peri-menopause,” negative alterations in 
body composition begin. Women gain weight, specifically subcutaneous FM and VAT, at 
accelerated rates14. A study with a large heterogeneous sample of women reported women 
entering the menopause transition experienced twice the increase in FM, paired with reduced 
LM, when compared to pre-menopausal controls15. More specifically, the distribution of fat also 
changes with menopause, with proportionally more VAT gain than subcutaneous FM12. These 
alterations in body composition are directly tied to CVD risk, which is the leading cause of death 
in women in the United States, accounting for about one of every five deaths2,16. Furthermore, 
aortic calcification, a measure of atherosclerosis, was found to be higher in post-menopausal 
women and continued to increase in the years following menopause3. Because estrogen plays a 




women have a heightened risk for a variety of diseases that are co-dependent on these 
dysfunctions. 
Estrogen also plays a role in bone and skeletal muscle health.  Women traversing 
menopause often experience loss of BMD and LM, resulting in greater risk for osteopenia, 
sarcopenia, and eventually osteoporosis5,6,17,18. Regarding muscle characteristics, evidence from 
mouse models suggests that estrogen is beneficial for optimizing muscle strength and quality, 
which was demonstrated by the rescuing effect of estradiol administration on the reduced force 
generated per milligram of contractile protein in ovariectomized mice17. Similarly, women with 
reduced estrogen have been shown to experience reduced muscle mass, muscle quality, and 
reduced strength during and following the menopause transition18,19. The effects of aerobic and 
resistance exercise for the prevention of chronic disease and improvement in muscular health are 
well documented, but this relationship has not been fully described throughout the stages of 
menopause. Clarifying the interplay between exercise capacity, body composition, and lifestyle 
factors in women at all stages of menopause remains paramount. 
Since nearly all women living past approximately 50 years of age will experience 
menopause, it is imperative to find strategies that reduce the symptoms and increased risk of 
chronic disease that accompany menopause. While the regulatory roles of estrogen on 
metabolism, body composition, and bone health at the physiological level are relatively well-
documented, research in women at all stages of menopause that ties together translational 
elements of metabolism, body composition, and lifestyle factors is lacking. Furthermore, the 
majority of research on this topic lacks all groups of women (i.e., pre- [PRE], peri- [PERI], and 
post-menopause [POST]) or uses technologically inferior methods of measuring body 




opposed to a 4-compartment (4C) criterion model, which allows for changes in bone density and 
total body water (TBW) to be accounted for. Additionally, important contributing lifestyle 
factors such as dietary habits, physical inactivity, and sleep need to be evaluated due to their 
interplay with chronic disease risk20. 
 
Purpose 
1) The primary purpose of this study was to comprehensively evaluate body composition 
derived from a 4C criterion model, muscle characteristics, metabolic parameters, and 
exercise capacity in women at all stages of the menopause transition (PRE, PERI, and 
POST).  
a) One comprehensive testing session was completed by all participants. Measurements 
included, body composition assessments, resting metabolic measurements, 
cardiometabolic blood marker assessment, an exercise test, and survey completion.  
b) Body composition variables of interest included FM, fat-free mass (FFM), percent fat 
(%fat), VAT, muscle characteristics (muscle cross-sectional area [mCSA] and echo 
intensity [EI]), waist to hip ration (WHR), and AG ratio. Metabolic variables of interest 
included REE, resting respiratory exchange ratio (RER), and change in metabolism 
during exercise, as indicated by change in RER. Survey variables of interest included 
physical activity, sedentary time, sleep quality, and number of menopause symptoms. 
2) The secondary purpose of this study was to identify relationships between body composition 




a) Body composition variables of interest included %fat and FFM. Lifestyle factors included 
number of pregnancies, physical activity, number of menopause symptoms, years since 
menopause in the POST group, and macronutrient intake. 
 
Research Questions  
1) Does body composition measured from a criterion 4C model (FM, FFM, %fat), BMD, VAT, 
and muscle characteristics differ between stages of menopause (PRE, PERI, POST)?  
a) More specifically, do FM, FFM, %fat, BMD, and VAT differ in PRE, PERI, and POST 
women? 
b) Does muscle size and quality (mCSA and EI) differ in PRE, PERI, and POST women? 
2) Are metabolic parameters (REE, RER, lipid profiles) different in women at various stages of 
menopause (PRE, PERI, POST)? 
a) At rest, do women expend different amount of energy (REE; kcal/day) or utilize different 
substrates, as determine RER, during different phases of menopause? 
b) During submaximal exercise, does menopausal status impact fuel utilization at varying 
intensity levels (i.e., metabolic flexibility), as indicated by change in RER? 
c) Do cardiometabolic blood markers (TC, LDL, HDL, and fasting blood glucose [GLU]) 
differ throughout menopause? 
d) After accounting for differences in age, estrogen, and progesterone, is there an 
independent impact of menopause on REE or RER at rest and/or during exercise? 
3) Do relationships exist between body composition (%fat, FFM) and lifestyle factors (physical 
activity, number of pregnancies, number of menopause symptoms, diet, years since 




a) Are these lifestyle factors related to body composition? 
 
Research Hypotheses 
1) As women traverse menopause, they will experience increased %fat, increased FM, increased 
VAT, decreased FFM, and decreased BMD.  
2) Muscle characteristics, specifically a reduction in mCSA and increase in EI, will be 
identified as women experience menopause after adjusting for age and skinfold fat thickness.   
3) REE will not differ significantly between PRE, PERI, and POST after accounting for 
differences in age.  
4) POST will expend fewer calories at rest while utilizing more carbohydrates, as indicated by 
an elevated RER, than PRE and PERI. 
5) As women progress through menopause, they will experience decreased metabolic flexibility 
during exercise, as demonstrated by a greater change in RER during exercise. 
6) Cardiometabolic blood markers will differ between groups of women; POST will have higher 
LDL, higher TC, lower HDL, higher triglycerides (TRG), and higher GLU than PRE and 
PERI. 
7) Number of years since menopause and number of pregnancies will be positively correlated 








1. Participants were pre-, peri-, or post-menopausal, as confirmed by screening, and 
were ages 35-60 years old.  
2. An equal number of normal weight and overweight/obese women stratified by body 
mass index (BMI; 18.5-24.9 kg/m² and 25.0-39.9 kg/m², respectively) were recruited. 
3. Pre-menopausal women were at least 35 years old and eumenorrheic for the previous 
12 months.  
4. Peri-menopausal women were at least 38 years old and experiencing irregular 
menstrual cycles but did not have had amenorrhea for more than 12 consecutive 
months.  
5. Post-menopausal women had completed the menopause transition and had an absence 
of menstruation for at least 12 consecutive months. 
6. The study consisted of one visit, encompassing all the body composition and 
metabolic testing in approximately 2 hours. 
7. Body composition was analyzed using a 4C model, using DXA, bioelectrical 
impedance spectroscopy (BIS), and air displacement plethysmography (ADP). 
8. Pre-menopausal participants were tested during the point at which estrogen levels are 
the lowest (i.e., early follicular phase of the menstrual cycle), and salivary estradiol 
and progesterone was used to account for differences in ovarian hormones. Peri-
menopausal women were tested during the early follicular phase if still having 
monthly menstruation; if participants had not had a period in >2 months, they were 




9. Participants were excluded if they were currently nursing or had a child in the 
previous 6 months. 
10. Participants were excluded if they had gained or lost >5kg in the previous 2 months. 
11. Participants were excluded if the health history questionnaire indicated a recent 
history of musculoskeletal disease, musculoskeletal injury, metabolic disorder, CVD, 
or eating disorder. 
12. Participants were excluded if they had undergone a partial or full hysterectomy for 
treatment of menopausal symptoms or had polycystic ovary syndrome (PCOS). 
13. Participants were excluded if they were morbidly obese (BMI > 39.9 kg/m²). 
14. Participants were excluded if they consumed phytoestrogen supplements. 
15. Participants were excluded if they were competitive athletes (i.e., >200 min/week of 














1. Subjects were recruited at the University of North Carolina at Chapel Hill and in the 
surrounding areas, therefore, recruitment of participants was not truly random. 
2. Results may have been influenced by birth control or hormone replacement therapy, 
but these potential effects were accounted for statistically by covarying for salivary 
estrogen levels. Few women consumed hormone therapy (n=4) and were on birth 
control (n=10).  
3. A small number of women with thyroid conditions (n=5) were included due to 
extensive durations (mean 12 yrs; range 4-27 yrs) of consuming thyroid-regulating 
medication. 
4. Dietary information was collected and compared but not used as a covariate.  
5. Subjects were not excluded based on having anxiety or depression, but conditions 
were documented. If consuming medications, participants must have been 
consistently taking the same medication at a constant dose for ≥ 9 months. 
6. The age range in PERI was large (41-57 yrs), which may have influenced results. 




1. Subjects provided accurate answers to screening questions. 
2. Subjects provided accurate and honest answers to diet, menopause symptoms, sleep 




3. Subjects adhered to pre-assessment guidelines, including fasting and abstinence from 
caffeine, alcohol, and tobacco.  
4. Calculation of 75% heart rate reserve (HRR) accurately represented 75% of maximal 
exercise intensity.  
 Statistical  
1. The sample of participants that were in the study were from a population that is 
normally distributed. 





Significance of Study  
 The aim of this study was to comprehensively evaluate and assess changes in body 
composition, metabolic parameters, and lifestyle factors in women at all stages of the menopause 
transition. While current literature has demonstrated that menopause induces detrimental body 
composition changes5,6,12,14 and produces a metabolically compromised phenotype11,12, the 
literature lacks data that assesses the interplay between metabolism, body composition, and 
lifestyle factors across the menopausal transition. Current literature either employs small or 
epidemiological sample sizes, making it difficult to draw substantial conclusions about 
relationships between body composition and metabolism. Furthermore, employing a 4C criterion 
model to assess body composition utilizing modern technology throughout the menopause 
transition was novel. The outcomes of this project may help lay the foundation for developing 
specialized and feasible exercise recommendations to address the physiological needs of women 







CHAPTER II: LITERATURE REVIEW 
Introduction 
 Menopause is the natural transition through which a woman’s ovaries shrink and 
reduce the production of ovarian hormones estrogen and progesterone, ultimately eliminating 
reproductive capabilities. The average age of menopause in the United Sates is 51 years old, and 
46 million women in the United States are projected to be menopausal by 20201,7. Because life 
expectancy has continually risen through the previous decades, women can spend up to 40% of 
their lives in the post-menopausal stage. Estrogen impacts and helps regulate many physiological 
processes outside of reproduction such as metabolism, so the dramatic drop in estrogen 
associated with menopause is likely related to adverse health outcomes and increased risk for 
disease including CVD, osteoporosis, and MetS2,4,6,8. The objectives of the current review were 
to analyze the literature on the effects of menopause on metabolism, body composition, and 
lifestyle factors, as well as to differentiate these impacts between pre-, peri-, and post-
menopausal women. A secondary objective was to analyze the literature regarding the efficacy of 
exercise to mitigate the negative changes in body composition and heightened disease risk that 
accompany the menopause transition.  
Overview of the Menopause Transition 
 Once completing the transition through puberty, women typically experience 
regular menstrual cycles, predictable fluctuations of ovarian hormones, and are considered 
eumenorrheic until they begin the menopause transition. A regular menstrual cycle in pre-




main phases21,22. At the beginning of the follicular phase (~14 days total), menstruation occurs 
and hormones including estrogen, specifically 17β-oestradiol (estradiol), progesterone, follicle 
stimulating hormone (FSH), and luteinizing hormone (LH) are at the lowest baseline levels21,23. 
Around day 4-5 of menstruation, the mid-follicular phase begins, and estrogen and FSH levels 
begin rising to prepare the body for ovulation; at the end of the follicular phase (day 11-13), LH 
levels spike and induce ovulation, while estrogen rises and then falls following ovulation. The 
luteal phase (14 days) begins on day 14 after ovulation occurs; LH and FSH decline and return to 
baseline levels while progesterone and estrogen levels peak around day 20-24 (mid-luteal phase) 
to prepare the body for pregnancy. The main roles of progesterone include preparing the 
endometrium for a fertilized ovum and facilitating and maintaining implantation of the blastocyst 
24. If pregnancy does not occur, hormone levels return to baseline and induce menstruation, 
signaling the beginning of a new 28-day menstrual cycle22. 
Women enter the menopause transition when they begin experiencing irregular menstrual 
cycles, with the average age of 40 years (peri-menopause). Irregular menstrual cycles often occur 
for 2 to 8 years25, and pregnancy is still possible, however, once a woman has been amenorrhoeic 
(no menstruation) for 12 consecutive months, she is considered post-menopausal and has lost 
reproductive capabilities7. Menopause may also be confirmed by having a FSH level of 30 
mIU/mL or higher from a blood test26. The menopause transition involves a multitude of slow 
changes in hormone levels, which ultimately cause the well-known symptoms of menopause 
including hot flashes, mood disturbances, thermoregulatory issues, and other vasomotor 
symptoms27. The literature robustly supports that ovarian hormones like estrogen and 
progesterone play vital roles in physiological health outside of reproductive function. Typically, 




homeostasis, so it can be difficult to isolate independent physiological effects of estrogen versus 
progesterone21. It is then important to compare the extent to which levels of sex hormones like 
estrogen and progesterone change as pre-menopausal women transition to the post-menopause 
stage of their lives. 
When analyzing how sex hormones change in the years leading up to, during, and after 
menopause, an extensive longitudinal epidemiological evaluation (study of Women’s Health 
Across the Nation [SWAN]) demonstrated that mean serum estradiol did not significantly change 
until about 2 years before the final menstrual period (FMP)28. Estradiol appears to continually 
decline through 2 years after the FMP and then stabilize; reported values of serum estradiol 2 
years prior and 2 years following the FMP were 54.08 pg/ml and 18.35 pg/ml, respectively 
(~66% decrease)28. Another longitudinal study found that estradiol changed significantly only in 
women who became post-menopausal12. The same SWAN study demonstrated that FSH started 
to rise about 6 years prior to the FMP, declined immediately before the FMP, and stabilized 
within 2 years after the FMP; reported mean FSH levels 2 years prior and 2 years following the 
FMP were 27.57 IU/liter and 91.58 IU/liter, respectively (~232% increase)28. Similarly, Lovejoy 
et al. 200812 demonstrated that all women experienced significant increases in FSH over 4 years, 
with the highest FSH levels observed in post-menopausal women. An older study assessed FSH, 
LH, estrogen, and pregnanediol, an inactive metabolic product of progesterone, in 20 pre-
menopausal women and 22 post-menopausal women via urine samples and observed an increase 
in FSH (IU/24hr) (0.7 in pre-menopause compared to 28.1 in post-menopause; ~40 times 
higher), an increase in LH (IU/24hr) (peaked at 7.2 in pre-menopause compared to 32.0 in post-
menopause; ~4 times higher), and a decrease in pregnanediol (μmol/24hr) (pre-menopause luteal 




Additionally, estrogens (nmol/24hr) peaked later in the cycle, with concentrations of 121.7 nmol 
in days 10-17 in pre-menopause compared to 25.5 nmol in post-menopause (~5 times lower)29. 
These observed hormonal changes are summarized in Table 1. Of important note, available 
evidence has reported that as BMI increases, metabolites of LH, FSH, estrogen, and progesterone 
decrease significantly but follow similar patterns30. Interestingly, these studies have also found 
that cycle length increases during the menopause transition, that African American women 
experience longer menopause transitions, and that women who enter peri-menopause earlier 
experience lengthened menopause transition duration31. The aforementioned sex hormones are 
not only responsible for their pivotal role in reproduction, but are simultaneously involved in 
other physiological processes including metabolism and regulation of body composition8.        
Energy Expenditure Through the Menopause Transition  
 Mounting evidence in both mouse models and humans suggests a regulatory role 
of estrogen on bioenergetics, energy expenditure, and body composition8. Mice are frequently 
used to help elucidate the mechanistic pathways of estradiol while reducing the confounding 
effects of aging. Whole-body knockout of estrogen receptor alpha (ERα) in female mice resulted 
in reduced energy expenditure, which was attributed to both lowered basal metabolic rate and 
activity32,33. Identifying the roles of estrogen in humans is more complicated, however, similar 
results have been found. At rest, eumenorrheic premenopausal women exhibit heightened fat 
oxidation, as indicated by decreased RER, and highest REE during the luteal phase of the 
menstrual cycle when ovarian hormones peak34,35. Interestingly, suppression of sex hormones 
through administration of gonadotropin releasing hormone agonist therapy (GnRH), for as little 
as 6 days, resulted in the reduction of REE significantly beyond REE measured during the early 




in altered energy expenditure: REE, sleeping EE (SEE), exercise EE (EEE), and TEE were 
significantly reduced in premenopausal women37. When GnRH was combined with estradiol 
therapy, the reductions in REE and SEE were abolished, indicating a rescuing effect of estradiol 
on some forms of energy expenditure37. Together, these findings demonstrate that sex hormones, 
specifically estrogen, likely impact the regulation of energy expenditure in healthy 
premenopausal women. As estrogen decreases through menopause, negative shifts in body 
composition and greater obesity-related disease risk are likely tied to altered energy expenditure, 
and possibly RER.  
Two studies that assessed TEE in women throughout the menopause transition found 
about a 9% reduction in post-menopausal women, while one of the studies found a 7% reduction 
in TEE in women who remained pre-menopausal12,38. REE is the typically the largest constituent 
of TEE, and it represents the baseline caloric requirement to support physiological processes39. 
REE in humans may be influenced by obesity, physical activity, age, and other factors like 
menopause status39,40. An early cross-sectional study that investigated resting metabolic rate in 
183 females ages 18-81 years using indirect calorimetry reported a curvilinear trend in the 
reduction of RMR over time for women 51-81 years, versus a linear decline in RMR in women 
18-50 years, suggesting that menopause may accelerate the age-related decline in RMR41. Based 
on the models generated from this study, authors predicted that women 18-50 years would 
experience a 0.6% reduction in RMR per decade, compared to a 4% reduction per decade in 
women 51-81 years41. It is hypothesized the larger decline is a result of both a decline in FFM 
and aerobic fitness41. A longitudinal 4-year study in 34 initially pre-menopausal women reported 
a significant drop in SEE (1,398 kcal/day to 1,287 kcal; 9%) during the post-menopausal phase 




from the post-menopausal women12. A more recent 5-year longitudinal study assessed REE in 91 
Caucasian women who were initially pre-menopausal and demonstrated no significant difference 
in REE38. Cumulatively, the impact of menopause on REE is unclear; the cross-sectional study 
reported an interesting and significant trend of decreasing REE around menopause, however, two 
longitudinal studies demonstrated no significant effects. Of note, the Lovejoy et al.12 study 
assessed SEE, which is similar but not equal to REE, and the Duval et al.38 sample only consisted 
of Caucasian females. The lack of significance in these studies could have been caused by 
insufficient sample sizes (average n=~35) or study length (4-5 years), which may not have been 
long enough to capture long-term effects of menopause.  
To assess the impact of menopause on energy expenditure via indirect calorimetry during 
exercise (EEE), one group cross-sectionally tested pre- (n=19), peri- (n=8), and post-menopausal 
(n=14) women by having them bike at 50% maximal oxygen consumption (VO₂max) for 45 
minutes42. Before adjusting for LM, post-menopausal women experienced lower EEE by 1.05 
kcal/min on average (19% reduction), which would have translated to ~47 fewer kcals expended; 
RER in post-menopausal women was 0.03 a.u. higher than pre-menopausal women, but this 
difference was not significant42. Following adjustment for LM, the difference in EEE was 
reduced to 7%, which no longer remained statistically significant42. Overall, very little data with 
sufficient sample sizes exists to evaluate the effects of menopause on EEE; further investigation 
is warranted.  
Metabolic flexibility is regarded as the ability to adapt or respond to conditional changes 
in metabolic demand of substrates; exercise is an activity that requires metabolic flexibility43. 
Studies have demonstrated that many factors such as training status, age, obesity, diabetes and 




optimize fatty acid oxidation, but these data are scarce43–46. A previously mentioned study that 
longitudinally assessed energy expenditure through menopause reported a 25.8 g/24hr decrease 
in fat oxidation in women who became post-menopausal; while metabolic flexibility during 
exercise was not a measurement outcome of this study, the results still suggest that post-
menopausal women may be more inclined to be metabolically inflexible12. Another cross-
sectional study reported similar EEE in pre-, peri-, and post-menopausal women, however, they 
found that fat oxidation in post-menopausal women during 45 minutes of cycling at 50% 
VO₂max remained significantly reduced following adjustment for LM42. Interestingly, despite no 
significant difference in RER, these authors reported that post-menopausal women experienced 
23% lower whole-body fat oxidation (0.21 g/min) compared to pre-menopausal women (0.31 
g/min), which was quantified using the following equation: fat oxidation (g/min) = 1.695VO₂ - 
1.701VCO₂42,47. This group also assessed markers of oxidative capacity by collecting muscle 
biopsies before and immediately after exercise in a subsample, reporting that post-menopausal 
women exhibited lower cytochrome c (CytC) protein level and lacked the increase in 
phosphorylated AMP-activated protein kinase (pAMPK) observed in pre-menopausal women42. 
Because CytC and AMPK are largely involved in oxidative capacity and regulation of 
bioenergetics, these findings also suggest that menopause may inhibit metabolic flexibility42. 
Body Composition Through the Menopause Transition  
Literature investigating the relationship between sex hormones, menopause, and body 
composition dates back to the 1980s, and despite enormous differences in methodology for 
assessing body composition, results are consistent with current literature. A foundational study 
reported higher estimated FM and lower LM in older postmenopausal women (~70 yrs) 




use of a 4C model (fat, protein, mineral, and water) to measure body composition was employed 
in 1996, evaluating 155 Caucasian women via tritiated-water dilution, DXA, and equations for 
protein, water, mineral, and fat49. Results reported that menopause was associated with increased 
FM, decreased LM, and decreased bone mass49. More recent literature has investigated more 
detailed changes in body composition and obesity throughout the menopause transition using 
advanced models that consider ovarian aging and include many covariates such as age, race, and 
time since FMP50. A recent prospective investigation leveraged SWAN data and assessed body 
composition via DXA, reporting a similar increase in FM and loss of LM throughout the 
menopause transition15. Of note, body composition changes were not congruent across all 
races/ethnicities, with Japanese and Chinese women demonstrating slightly different patterns15. 
While studies like SWAN incorporate large, multi-racial groups of women, it is important to note 
that data regarding regional body composition, muscle characteristics, VAT, and updated 4C 
body composition analyses in women traversing the menopause transition are still lacking. The 
following sections will describe changes in body composition elements (FM, LM, bone) in more 
detail and highlight knowledge gaps in the literature.  
Fat Mass 
 
The reduction in estrogen, specifically estradiol, is directly related to negative shifts in 
body composition and other physiological health outcomes8. Whole-body knockout of ERα in 
female mice resulted in twice the amount of fat gain, demonstrating the potential regulatory role 
of estradiol on adiposity51. Another study in ovariectomized mice found that estrogen 
replacement treatment resulted in reduced adipose mass and adipocyte size, as well as down-
regulation of lipogenic genes52. This group also demonstrated that estradiol may promote 




proliferation activator receptor-delta (PPARδ)52. In contrast, a study in ovariectomized rats found 
that estrogen treatment rescued the activity of lipid oxidation enzymes, while progesterone 
treatment lacked this rescuing effect; treatment with estrogen and progesterone yielded similar 
results to the control group, which indicates that progesterone likely acts antagonistically to 
estrogen regarding fat oxidation53. 
As obesity and obesity-related disease prevalence in humans increase in the United 
States, with proportionally more overweight and obese women than men, it is important to 
consider how menopause effects the rate of subcutaneous fat gain54. When comparing 
differences in %fat cross-sectionally between pre- and post-menopausal women, many studies 
have demonstrated that post-menopausal women exhibit significantly higher %fat and greater 
FM than their pre-menopausal counterparts49,55,56. One study that utilized DXA, reported a 6% 
higher body weight, 28% higher FM, and 17% higher %fat in postmenopausal women, with the 
differences in FM persisting after adjusting for age and weight57. A recent meta-analysis that 
incorporated data from 478,734 pre-menopausal and 571,185 post-menopausal women similarly 
reported that FM, BMI, weight, %fat, waist circumference, hip circumference, wasit:hip ratio, 
visceral fat, and trunk fat percentage were significantly greater in post-menopausal women58. 
However, when assessing the longitudinal data in this meta-analysis, the rates of change in BMI 
and %fat were similar to annual increases attributed to age in another study of women aged 18-
45 years, indicating that menopause may not have a direct impact on BMI or %fat, but rather 
likely influences fat distribution58,59.  
Retrospective, cross-sectional studies that assess the effects of menopause on body 
composition lack the ability to consider when the FMP occurred, as well as fail to track minute 




composition, providing better insight into the causal relationship between menopause and FM 
gain15. Results from one recent SWAN study of 1,246 multi-racial women reported that the 
average rate of fat gain increased to 1.7% per year (average 0.45kg/year) from 1.0% per year 
(average 0.25kg/year) at the beginning of the menopause transition, which persisted through two 
years following the FMP. Interestingly, Caucasian and African American women experienced 
similar, above-average rates of FM gain per year during the menopause transition (2.11%), while 
Japanese and Chinese women did not experience FM gain during the menopause transition15. 
This data provides compelling evidence that menopause independently influences FM gain. In 
contrast to FM, this group found that weight increased linearly throughout pre-menopause 
without acceleration through the menopause transition, indicating that weight gain alone may not 
be independently influenced by menopause15. This study also analyzed the role of age at FMP 
and found that women who had later FMPs experienced 0.23% smaller annual increases in FM 
during the menopause transition15.  
While the effects of menopause on FM gain have been studied extensively, it is also 
necessary to consider the effects of menopause on regional fat distribution, particularly VAT. 
VAT encompasses the adipose tissue that surrounds intra-abdominal organs, and is also 
commonly referred to as abdominal obesity, visceral obesity, and/or central obesity in the 
literature60. Computed tomography (CT) and magnetic resonance imaging (MRI) are currently 
the gold standards for measuring cross-sectional area or volume of VAT; DXA and ultrasound 
have been shown to be valid methods for quantifying VAT60,61. When accounting for age and 
total body fat, previous data has demonstrated nearly 50% more intra-abdominal fat in 
postmenopausal women, compared to premenopausal women57. Similarly, a longitudinal study 




experienced a significant increase in VAT (mean increase 9.5 cm²) that was accompanied by a 
significant decrease in serum estradiol (mean decrease 62.9 pg/ml)12. Similarly, when adjusting 
for %fat, age, race, depression, and physical activity, postmenopausal women had on average 8.6 
cm² more VAT than premenopausal women; these authors also found that bioavailable 
testosterone was a stronger predictor of VAT than estradiol, suggesting that testosterone may 
induce male-pattern fat distribution in postmenopausal women, especially when estradiol is 
simultaneously reduced62. In contrast, a study on VAT accrual in groups of women (pre-, peri-, 
and post-menopause) at two time points (average 7 years apart) found that women experienced 
increased VAT over time, but the rate at which this gain occurred was not dependent upon 
menopausal status, suggesting that increases in VAT may be due to aging alone63. It is important 
to note that this study only assessed VAT at two distant time points as opposed to the other 
longitudinal studies that assessed body composition once per year for at least 4 years, so this 
group may have been unable to detect minute changes in VAT throughout menopause.  
The idea that menopause results in an increase of both subcutaneous FM and VAT 
warrants further investigation into the impact of menopause on regional distribution of fat gain. 
Waist and hip circumference measurements are a simple and cost-effective way of characterizing 
changes in regional fat distribution. A cross-sectional study in 324 pre-, peri-, and post-
menopausal women demonstrated that 50% of post-menopausal women had a waist 
circumference greater than 88.0 cm (abdominal obesity), compared to only 27.0% of pre-
menopausal women64. Similarly, over 80% of post-menopausal women had a waist:hip ratio 
greater than 0.8 compared to 48.8% of premenopausal women64. After adjusting for age, BMI, 
education, hormone use, physical activity, alcohol consumption, and smoking, this group found 




greater than 88.0 cm, indicative of abdominal obesity64. In contrast, a longitudinal SWAN study 
measured waist circumference annually for 3 years in 3,064 women and failed to find that 
increases in waist circumference were dependent on menopause; however, the authors noted that 
waist circumference tended to be higher in the women who became post-menopausal during the 
3 year period (13% of total sample)65. Similarly, another longitudinal study failed to report a 
significant interaction between waist:hip ratio and menopause status. This group reported pre-
menopausal women with greater waist:hip ratios had significantly lower estradiol levels, 
however, greater waist:hip ratios in post-menopausal women were associated with greater 
estradiol levels66. Relationships between wasit:hip ratio and menopause require further 
investigation because current literature is inconclusive, and many studies only assess waist 
circumference as a proxy for abdominal fatness, as opposed to assessing waist and hip 
circumferences in conjunction. 
Lean Mass 
 
LM is highly associated with all-cause mortality in older adults (>65 yrs). Concomitant 
decreases in LM reported with menopause may result in greater disease susceptibility in the  
decades following menopause67,68, although the influence of menopause on LM is not clearly 
understood. One cross-sectional study reported no differences in FFM or appendicular skeletal 
muscle mass in pre- and post-menopausal women57. Similarly, a longitudinal study that assessed 
women annually for 4 years did not find a significant difference in LM in women who became 
post-menopausal12. In contrast, a cross-sectional study that included women aged 18-79 years 
found that LM significantly decreased an average 2.7 kg each decade from 40 to 60 years, with 
the loss attributed to menopause55. The previously mentioned prospective SWAN study found 




study reported similar changes in all races and ethnicities included, as well as no independent 
effect of FMP on LM loss15. While these changes in LM may seem too small to be clinically 
relevant, the SWAN study cumulatively reported that the average 3.5 year menopause transition 
was accompanied by an average 0.5% decrease in LM and 6% total gain of FM, resulting in an 
average 3.6% increase in %fat15. One limitation of these studies results from using DXA alone to 
assess LM; while authors excluded bone in LM calculations, they were unable to distinguish 
differences in water. Employing a 4C model of body composition analysis in the proposed study 
will allow for more precise measurements of LM and TBW between groups of women. 
Muscle Characteristics 
 
Muscle quality (MQ) may be operationally defined multiple ways. For example, MQ may 
be defined as the peak torque produced during eccentric or concentric contractions per unit of 
muscle mass or by using EI, which is an index of MQ generated through gray-scale analysis of 
pixels within an ultrasound image that indicates infiltration of fat and fibrous tissue into the 
muscle69,70. Aging results in decreased muscle quality and force production, however, women 
experience rapid loss of strength after age 55 (menopause), compared to the linear decline in 
strength over time that men experience19. Furthermore, peri-menopausal women who received 
estrogen-based hormone therapy did not experience the loss in strength that peri- and post-
menopausal women experienced without hormone therapy, demonstrating the potential role of 
estrogen in muscle physiology19. Some authors have hypothesized that estrogen provides benefits 
regarding muscle quality over muscle quantity via estrogen receptors and improvement of 
myosin function, by acting as an antioxidant or as a membrane stabilizer, but little research exists 




A study that compared post-menopausal Korean women who did and did not use 
hormone therapy found that MQ was similar between groups when MQ was defined as absolute 
isometric knee extension strength (iKES) relative to BMI as well as iKES relative to 
appendicular LM72. A large cross-sectional study in men and women found similar impacts of 
aging on decreases in MQ, with the exceptions of greater overall decrease in MQ in men and a 
20% greater decrease in leg MQ than arm MQ in women over time69. A study that assessed hand 
grip strength cross-sectionally in Brazilian pre-, peri-, and post-menopausal women found that 
even after adjusting for age, family income, education, BMI, and other confounders, post-
menopausal women exhibited significantly lower hand grip strength73. While aging is associated 
with reduction in strength, mCSA was found to account for only 39% of this reduction in elderly 
adults, so further investigation of MQ and mCSA is necessary74. More specifically, FM gain 
through the menopause transition is common, and lower MQ (greater fat and fiber infiltration) is 
associated with reduced whole-muscle force production15,75,76. Lastly, a recent study identified 
that the amount of muscle fat was inversely correlated with bone marrow density in osteoporotic 
women; further research on MQ through menopause is warranted due to the potential 
relationship of MQ and bone physiology77. 
Bone Mineral Density 
 
Osteoporotic bone loss is incited by the reduction of estrogen and the concomitant 
increase in bone resorption, which is demonstrated by ovariectomized mice developing 
osteoporosis and many other studies that implicate ERα as the main mechanism through which 
estrogen prevents bone loss6,78. One instance in which estrogen and progesterone likely act 
synergistically involves preventing bone loss; estrogen prevents bone loss by reducing bone 




its ability to act as a ligand for glucocorticoid receptors79. Glucocorticoids are associated with 
bone loss because they have the ability to block osteocalcin synthesis induced by vitamin D, so 
progesterone slows bone loss that would have been triggered otherwise by glucocorticoids79,80. A 
recent review also summarized the effects of FSH on bone physiology, pointing out that FSH 
receptors are present on osteoclasts but not osteoblasts, that FSH promotes osteoclast 
differentiation and survival, and that more longitudinal studies on FSH and bone health are 
necessary to determine a direct relationship in humans81. FSH may be independently related to 
bone loss; one SWAN study reported estradiol as a weak predictor of BMD loss and FSH a 
stronger predictor due to its steady increase over time82.  
An older cross-sectional study assessed BMD at the spine, hip, and radius using DXA in 
981 white women aged 50-98 years, and found that the steepest rate of decline (slope) in BMD 
occurred from ages 50-59 years at the femoral neck and ultradistal radius sites, further indicating 
that menopause and estradiol loss accelerate bone loss more extensively than the impact of aging 
alone83. Further analyses in this cohort of estrogen therapy users (never used, past user, and 
current users) reported only the women currently using this therapy experienced greater BMD 
than non-users and past-users83. Prospective, longitudinal SWAN studies have extensively 
assessed BMD loss through menopause in multi-ethnic samples. One study of ~850 women not 
receiving hormone therapy or osteoporosis treatment unsurprisingly found that BMD 
significantly decreased during a 10-year period, however, they were able to reveal that the 
majority of BMD loss occurred in the time that spanned 1 year prior to the FMP through the 2 
years following the FMP84. Lumbar spine BMD decreased by 10.6% over 10 years (1.066 
gm/cm² to 0.953 gm/cm²), but 7.38% of this loss occurred in the 3 years surrounding the FMP; 




gm/cm²) with 5.8% of this loss occurring in the same 3-year timespan84. This group also 
demonstrated that African American women experienced slower BMD loss by 1%, while 
Chinese women experienced 2% higher BMD loss84. Higher BMI was also associated with 
slightly lower (0.28%) but statistically significant BMD loss, which was likely due to the shift in 
more estrogen production from adipose tissue84. Similarly, an 18-year longitudinal SWAN study 
assessed trabecular bone score (TBS), a predictor of bone fractures independent of BMD, and 
found that prior to the menopause transition, TBS was unchanged85. However, an average 
decline of 1.16% in TBS was observed 1.5 years before the FMP, which slowed to 0.89% two 
years after the FMP; African American women experienced lower decreases in TBS, whereas 
Japanese women incurred similar decreases as white women85. 
Effects of Menopause on Lifestyle Factors 
Physical Activity   
 Higher physical activity is associated with decreased all-cause mortality in adults; 
understanding physical activity patterns and physiological effects around the menopause 
transition may help identify potential causes of increased disease risk86. A recent randomized 
control trial in 61 pre-menopausal women evaluated two treatment groups (GnRH+estradiol and 
GnRH+placebo) and reported that time spent engaging in moderate to vigorous exercise was 
better maintained in the GnRH+estradiol group, and at 4-months of tracking, the 
GnRH+estradiol group exhibited a significantly higher amount of time spent doing moderate to 
vigorous exercise87. Little research exists assessing physical activity through menopause, but the 
most compelling evidence was reported by Lovejoy et al. in 200812. Utilizing accelerometry, this 
4-year longitudinal study found that during the menopause transition, physical activity energy 




kcal/day greater 3-4 years prior to menopause, followed by stabilized activity expenditure in the 
two years following menopause12. In contrast, a study in over 1,000 Finnish women aged 45-64 
years quantified physical activity by surveying metabolic equivalent (MET) hours per week, and 
results showed that nearly 30% of women who entered the menopause transition or became 
postmenopausal, increased their physical activity, although this difference was not statistically 
significant88. Authors hypothesized that this increase in physical activity was likely due to 
increased motivation to make lifestyle changes and prevent weight gain88. A SWAN study 
assessed baseline physical activity using the Kaiser Physical Activity Survey when women were 
pre- or early peri-menopausal followed by physical function assessments (40-foot walk, chair 
stands, grip strength) approximately 15 years later. General findings concluded that women who 
exercised more in mid-life performed better on the functional tests during the follow-up visit, 
indicating that understanding changes in physical activity during the menopause transition may 
be key in predicting declines in mobility, as well helping to prevent these clinically-relevant 
declines in functionality89.  
Diet and Energy Intake 
When interpreting energy expenditure and body composition changes through 
menopause, it is important to consider potential alterations in energy intake and/or diet. Studies 
have demonstrated that ERα-knockout mice exhibit increased energy intake and reduced energy 
expenditure compared to wild-type mice, indicating that estrogen may play a role in regulating 
energy intake33,51,90. The longitudinal study performed by Lovejoy and colleagues12 measured 
dietary intake in initially pre-menopausal women via annual 4-day logs and reported 
significantly greater total energy intake 4 years prior (2,270 kcal/day) to entering the menopause 




two years following menopause, saturated fat (18 g/day to 27 g/day) and cholesterol (210 mg/day 
to 344 mg/day) intake was significantly higher than at menopause onset12. Another longitudinal 
study (n=38) quantified energy intake via 7-day food logs and reported a similar decrease in 
energy intake from 2,099 kcal/day to 1,845 kcal/day91. These women also demonstrated 
significantly reduced carbohydrate intake from 269 g/day to 230 g/day91.  Dietary habits may 
change during and after the menopause transition; whether these changes are stimulated by 
behavioral or physiological influences has yet to be identified. 
Sleep 
 
Sleep quality is often operationally defined by self-reported measures of subjective sleep 
quality, time it takes to fall asleep, sleep duration, number of disturbances throughout the night, 
and feelings of tiredness or dysfunction the following day92. While the gold standard would 
involve testing participants overnight in a sleep laboratory, this methodology is expensive and 
unrealistic, so oftentimes sleep quality is assessed via questionnaires93. It is important to assess 
sleep quality through menopause, as reductions in sleep quality may translate to negative impacts 
on quality of life and perceived energy. In animal models, evidence suggests that hormones like 
estrogen and progesterone may impact sleep cycles and sleep quality. One study in 
ovariectomized rats found that injections of estrogen plus progesterone produced the most 
similar sleep-wakefulness cycles as wild-type rats, suggesting that disturbances in sex hormones 
may influence sleep patterns94. A cross-over study in post-menopausal women assessed the 
effects of short-term estrogen therapy versus placebo on sleep quality;  total time spent asleep 
and time spent in different sleep stages were not affected by estrogen treatment, however, body 
movement arousals were lower and sleep quality was improved95. Reports from the Pittsburgh 




menopause transition, with sleep quality reducing linearly. Daytime sleep dysfunction did not 
appear to differ between menopausal stages; in contrast, sleep medication use was reportedly 
higher in late menopause96. Data from a SWAN study and a recent review confirm that 40-60% 
of menopausal women struggle with sleep problems, and women experience lower quality sleep 
with greater frequency of vasomotor symptoms97,98. 
Menopause and Disease Risk 
 
Because menopause induces alterations in metabolism, body composition, and lifestyle 
factors, it is crucial to identify the impact of menopause on disease risk for CVD, MetS, and 
osteoporosis. As of 2016, CVD (coronary heart disease, heart failure, stroke, and hypertension) 
was the leading cause of death in the United States, with nearly 3 million deaths recorded16. 
Globally, CVD accounted for approximately 17.6 million deaths in 2016, which was nearly a 
15% increase from 200616; a 2011 review highlighted that more women in the United States have 
died from coronary artery disease than men since 1984, and this disease accounts for 
approximately 1 of 6 deaths in women99. A recent SWAN study measured carotid-femoral pulse-
wave velocity (cfPWV), a proxy measurement for arterial stiffness, at varying stages of 
menopause and reported a significant 5.74% increase in cfPWV (adjusted for hormone therapy, 
smoking, blood pressure, waist circumference, and cholesterol) within 1 year of the FMP100. 
Another study reported aortic atherosclerosis was present in 12% of post-menopausal women, 
compared to only 3% of pre-menopausal women, with atherosclerotic risk 3.4 times higher in 
post-menopausal women3. Body composition in post-menopausal women has been shown to be 
an important risk factor for CVD12,31. Cumulatively, the literature suggests that obesity and 
greater VAT are associated with hypertension and augmented CVD risk 101,102. Because women 




imply greater CVD risk associated with menopause are logical. Despite having a normal BMI, 
post-menopausal women with greater trunk fat had greater risk of CVD, indicating that 
abdominal obesity plays a larger role in determining CVD risk, opposed to BMI or FM alone2. 
Greater waist:hip ratio was also associated with greater cholesterol and GLU levels; post-
menopausal women with waist:hip ratios of 0.84 or greater had increased prevalence of 
displaying CVD risk factors103.  
MetS is a broad condition that incorporates many precursors and risk factors for both 
CVD and Type 2 diabetes, which includes central obesity, hypertension, high GLU, and 
dyslipidemia104. MetS in women is globally determined as having three of the following 
qualifications: triglycerides ≥ 150 mg/dL, HDL < 50 mg/dL, blood pressure ≥ 130/85 mmHg, 
GLU ≥ 100 mg/dL, and/or waist circumference ≥ 88.0 cm105–107. Data from the National Health 
and Nutrition Examination Survey established that prevalence of MetS increased from 16% in 
women under 40 years to 37% in women ages 40-59 years, to 54% in women over 60 years108. 
Menopause is also associated with increased TC and LDL109,110. TC and LDL were highest in 
early post-menopause (206.3 mg/dL, 123.4 mg/dL) compared to pre-menopause (196.7 mg/dL, 
116.3 mg/dL)110. Triglycerides followed a similar trend of increasing to peak levels during early 
post-menopause (106.4 mg/dL), however, they remained elevated in late post-menopause110. 
Women in the quartile with greatest weight demonstrated the smallest changes in TC and LDL, 
which authors attributed to greater BMI levels being associated with higher estradiol levels110,111. 
Menopause may exacerbate negative lipid profiles, insulin insensitivity, and MetS further than 
aging alone, which is likely due in-part to unfavorable body composition changes paired with 




Osteoporosis is another condition exacerbated by menopause; osteoporosis is a skeletal 
condition characterized by decreased BMD that ultimately results in reduced bone strength and 
greater risk of bone fractures. There are two subtypes of osteoporosis: Type 1 osteoporosis 
affects mostly post-menopausal women and is caused by estrogen deficiency, whereas Type 2 
osteoporosis occurs in both men and women and is caused primarily by aging alone112. SWAN 
studies have identified that the menopause transition is a key period during which accelerated 
bone loss occurs (lumbar spine BMD 2.2% mean annual decline; femoral neck BMD 1.8% mean 
annual decline), and that if precautionary nutritional and exercise strategies are not implemented, 
women will have an exacerbated risk of osteoporosis in future decades, particularly during 
menopause113. An overview of changes in body composition and disease risk through the 
menopause transition is summarized in Figure 1. 
Exercise as a Modulator 
 
Physical activity has been reported to be an appealing strategy to counteract the negative 
health consequences of menopause and improve quality of life114–116. While the literature 
demonstrates that physical activity has marginal to beneficial effects on menopause symptoms114, 
a wealth of evidence supports that regular physical activity is associated with decreased risk of 
CVD, stroke, obesity, diabetes, osteoporosis, and mental health disorders, which is especially 
relevant in the context of menopause114,117,118. Improved health outcomes in menopausal women 
have been reported from a wide variety of exercise regimens. One study in obese middle-aged 
women (mean 40 yrs old) found that treadmill running for 30 minutes at 60-70% heart rate 
reserve combined with full-body resistance training 3 days per week for 12 weeks decreased 
weight, %fat, diastolic blood pressure, blood glucose, triglycerides, and increased HDL 119. 




moderate intensity once a week for 12 weeks decreased BMI, resting heart rate, systolic blood 
pressure, and TC 120. A pilot study in 12 obese women (mean 46 yrs old) found that Bikram yoga 
performed in 90-minute sessions 3 times per week for 8 weeks significantly improved glucose 
tolerance and decreased weight and %fat121. A meta-analysis also found that walking 
interventions, at least 4 weeks long, promoted significant reductions in BMI, body weight, and 
%fat in peri- and post-menopausal women122. High intensity interval training (HIIT) in post-
menopausal women (20 min 3x/week) resulted in increased trunk LM and total body LM123. 
Furthermore, increased physical activity is associated with improved bone maintenance124; even 
low intensity exercise like walking appears to afford worthwhile improvements in BMD in peri- 
and post-menopausal women when performed consistently for at least 6 months125,126. Lastly, 
another meta-analysis identified that resistance training, especially combined with weight-
bearing exercise, improved retention of femoral neck and lumbar spine BMD in post-menopausal 
women127. Together, these findings support that physical activity in many forms is a cost-
effective means of reducing disease risk with minimal chance of adverse side effects114. 
Conclusions  
Menopause is the transition through which women lose reproductive capabilities that is 
associated with hormonal, metabolic, and body composition changes over a relatively short 
amount of time. Due to the ability of estrogen to act as a master regulator of bioenergetics and 
body composition, the reduction in estradiol throughout the menopause transition is believed to 
influence body composition and metabolism in menopausal women8. While animal models have 
provided substantial evidence regarding the mechanistic pathways through which estradiol 
influences female physiology, growing evidence in pre-, peri-, and post-menopausal women 




energy expenditure and reduced fat utilization, however, REE and metabolic flexibility during 
exercise in women throughout menopause remain largely unexplored12,42. Large-scale 
longitudinal studies have identified that during the menopause transition, women gain FM with 
greater change in abdominal fat, lose LM, and experience reduced BMD to a greater extent than 
the implications of aging alone15,84. While available data have provided profound insight 
regarding body composition changes, they primarily employ DXA technology, which is unable 
to distinguish differences in total body water, a highly variable compartment in women. Further 
research utilizing 4C methodology is warranted, as well as investigation into the effects of 
menopause on muscle characteristics (muscle size and quality). Together, changes occurring 
through the menopause transition cumulatively promote increased risk of CVD, MetS, and 










CHAPTER III: METHODOLOGY 
Subjects 
 The proposed study aimed to enroll and test 72 healthy females stratified by menopausal 
status. We aimed to enroll 24 pre-menopausal women, 24 peri-menopausal women, and 24 post-
menopausal women, with an equal number of women stratified by BMI (18.5-24.9 kg/m² and 
25.0-39.9 kg/m², respectively; n=12 per menopausal group). Regarding sample size, measures of 
body composition (FM, LM) and REE sampled in pre- and post-menopausal women in similar 
studies indicated an effect size of approximately 0.512,14. To determine sample size for the 
current study primary outcome variables were used; FM data reported in Lovejoy et al.12 and 
REE data from our laboratory, with an assumed an effect size of 0.5, 80% power, and an alpha 
level set a priori at 0.05. Calculations indicated that the study will be sufficiently powered with a 
total sample size of n=65 participants. To allow for equal groups and account for a 10% dropout 
rate, we aimed to enroll 72 participants. Power was calculated using G*Power Version 3.1.9.2, 
with an analysis of variance (ANOVA) F-test. 
Women were tested during the point in which estrogen would be in the lowest 
concentrations (i.e., follicular phase of the menstrual cycle). Pre-menopausal and PERI women 
tracked their menstrual cycle and were scheduled for testing within a 7-day window after 
menstruation onset if still having regular cycles. If PERI women had not had a period for >2 
months, the visit was scheduled at their earliest convenience. Obtaining saliva samples allowed 
us to account for 17 β-estradiol and progesterone (P4) hormone levels. Participants were eligible 




least 35 years old and eumenorrheic for the previous 12 months. Peri-menopausal women were 
at least 38 years old and experiencing irregular menstrual cycles (i.e., recent change in 
frequency, duration, flow), but not have had amenorrhea for more than 12 consecutive months. 
Post-menopausal women had completed the menopause transition and had an absence of 
menstruation for at least 12 consecutive months. Women were excluded if they were younger 
than 35 or older than 60 years of age. Participants were eligible if they had a BMI between 18.5-
39.9 kg/m² and had no contraindications to submaximal exercise.  
Potential participants were excluded if they were: 1) currently pregnant or planning to 
become pregnant; 2) currently nursing or had a child within the previous 6 months; 3) gained/lost 
>5kg in the previous 2 months; 4) diagnosed with musculoskeletal disease or musculoskeletal 
injury limiting daily activities in the previous 3 months; 5) had a self-identified or clinically 
diagnosed eating disorder; 6) diagnosed with a disease that may result in significant changes in 
TBW (i.e., renal disease); 7) consumed anxiety/depression/thyroid medications for <9 
consecutive months; 8) had a change in dosage or medication for anxiety/depression/thyroid 
medication within 9 months; 9) underwent a full or partial hysterectomy; 8) diagnosed with 
metabolic disease [CVD, diabetes (Type 1 or Type 2)]; 10) consumed metabolism-altering drugs 
or medications outside of estrogen replacement therapy (i.e., stimulants, insulin) or 
phytoestrogens; 11) BMI > 39.9 kg/m²; 12) diagnosed with PCOS; 13) were competitive athletes 




Experimental Design  
 
The project employed a cross-sectional design and included one comprehensive 
laboratory visit that incorporated all body composition and metabolic assessments at one 
timepoint. This visit lasted approximately 2 hours. Prior to the testing visit, individuals were 
verbally screened for eligibility. During the screening call, participants provided verbal consent 
and then provided written consent prior to filling out the online surveys using a form approved 
by the University’s Institutional Review Board ensuring the protection of human subjects. 
Participants were asked to complete an online health history questionnaire as well as lifestyle 
questionnaires (physical activity, sleep, menopause status, and diet) prior to arrival. Upon arrival, 
participants were asked to provide a urine sample used to determine pregnancy status and 
hydration via urine specific gravity. A saliva sample was collected to determine estrogen and 
progesterone concentrations. Anthropometric measurements were taken next, followed by an 
REE assessment, a finger prick for measurement of cardiometabolic blood markers, body 




 Body composition was assessed using the 4C model described by Wang et al.128 to 
determine %fat, FM, and FFM. The equation that was used for calculating FM is displayed in 
Equation 1 where BV= body volume, TBW= total body water, Mo= total body bone mineral 
content, and BM= body mass.  
Equation 1: FM (kg) = 2.748 (BV) – 0.699 (TBW) + 1.129 (Mo) – 2.051 (BM). 
Once FM was calculated, %fat was calculated using Equation 2. 




Fat-free mass was calculated using Equation 3. 
Equation 3: FFM (kg) = BM – FM. 
The criterion measure used BIS for measures of TBW, ADP to estimate BV, and a full-body 
DXA scan to measure total bone mineral content (BMC; Mo = BMC x 1.0436). VAT was 
measured via brightness (B)-mode ultrasound using a curvilinear probe129. Participants were at 
least eight hours fasted and refrained from vigorous exercise for at least 48 hours and caffeine 
consumption for at least 12 hours prior to testing130,131. 
Dual-Energy X-Ray Absorptiometry  
 
Each participant underwent a full-body DXA scan (GE Lunar iDXA, GE Medical 
Systems Ultrasound & Primary Care Diagnostics, Madison, WI, USA). All participants were 
confirmed not pregnant from a urine pregnancy test. Participants were asked to remove all metal, 
thick clothing, and heavy plastic to reduce interference with the scan. Participants were 
positioned supine in the center of the scanning table. The scans were automatically analyzed by 
the software (encore Software Version 16), but specific regions of interest were confirmed by the 
technicians. BMC was obtained from this scan and multiplied by 1.0436 to determine Mo for the 
4C criterion model. Android and gynoid fat distribution, BMC, bone mineral density (BMD), 
and z-scores were recorded and analyzed.  
Bioelectrical Impedance Spectroscopy 
 
To assess TBW, intracellular fluid content (ICF), and extracellular fluid content (ECF), a 
multi-frequency bioelectrical impedance device was used (SFB7 ImpediMed, Queensland, 
Australia [10 – 500 kHz]). Participants laid supine on a table with arms separated from the torso 
and enough space between the legs to ensure no contact. Two electrodes were placed 5 cm apart 




of the right ankle and foot. Prior to testing, height, weight, age, and sex were entered into the 
device. Device software automatically estimated TBW, ICF, and ECF. The average of two trials 
was recorded as the TBW measurement. 
Air Displacement Plethysmography 
 
Prior to each BV measurement, the ADP device (BodPod®, COSMED USA, Inc., 
Concord, CA, USA) was calibrated according to manufacturer guidelines. In a private room, 
participants were asked to wear a swim cap and tight-fitting clothing such as a bathing suit or 
compression shorts/sports bra, and to remove all metal including jewelry, watches, and glasses 
prior to measurement to reduce isothermal air. Body mass was measured to the nearest 0.01 kg 
using the software’s corresponding scale. (Tanita Inc., Tokyo, Japan). Subjects were asked to sit 
upright in the BodPod, to breathe normally, and to minimize movement. Body volume was 
measured by a minimum of two trials that were within 150 mL of each other. 
Muscle Characteristics 
 
Muscle characteristic measures of the vastus lateralis (VL) were determined using a B-
mode ultrasound (Logiq-e, GE Healthcare, Wisconsin, USA) from panoramic scans taken at the 
thigh (Depth=6 and Gain=52) for all participants. The same technician performed each scan 
while the subjects laid supine with the right leg extended and relaxed on the examination table. 
To measure mCSA and EI, a technician performed a panoramic scan at 50% of the length of the 
femur. A correction factor for subcutaneous thigh fat thickness (THfat), previously described by 
Young et al.132, was used to account for the influence THfat has on EI measures (Equation 4), 
where y1 = raw EI, x =THfat, cf = 40.5278, and EIC = corrected EI. 
Equation 4: EIC (a.u.) = y1 + (x * cf). 




border of the VL taken at the distal, medial, and lateral sites and averaged. Muscle size (mCSA) 
was adjusted for body size by dividing mCSA by height in meters squared. All measures were 
analyzed using Image-J software (NIH, Bethesda, MD) by the same technician. Reliability of 
mCSA and EI in the present study is as follows: mCSA intra-class correlation coefficient (ICC)= 
0.99, standard error of the measurement (SEM)= 0.43 cm2; EI ICC= 0.99, SEM= 0.41 a.u. 
Waist to Hip Ratio 
 
Waist and hip circumferences were measured to the nearest 0.1 cm using a flexible 
inelastic plastic tape measure while the participant stood with equal weight on each leg with their 
feet approximately 20 centimeters apart133. Waist circumference was measured at the smallest 
point between the lower rib and iliac crest parallel to the floor133. Hip circumference was 
measured at the level of the widest circumference over the buttocks133. Two trials were 
performed for each measurement, and if the results were within 1 centimeter, the numbers were 
averaged. If the two trials were not within 1 centimeter, the two trials were be repeated. Waist to 
hip ratio (HWR) was calculated as waist circumference (centimeters) divided by hip 
circumference (centimeters)133.  
Resting Energy Expenditure 
 
 REE and substrate utilization were evaluated using a ventilated canopy with indirect 
calorimetry. Before each measurement, the metabolic cart underwent both flow calibration using 
a 3-liter syringe and gas calibration using a standard gas concentration. For 30 minutes (with the 
first 5 minutes discarded), subjects laid supine, while respiratory gases, oxygen update, and 
carbon dioxide production were analyzed over 15-second intervals with a metabolic cart 
(TrueOne 2400, Parvomedics, Inc., Sandy, UT). REE was determined in kcals/day using 




Equation 5: REE (kcal/min) = [(3.9 ∗ (VO₂(L ∗ min−1))) + (1.1 ∗
              VCO₂(L ∗ min−1)))] ∗ 1,440 min 134. 
RER was used to determine substrate utilization, and was calculated using Equation 6:  






Metabolic flexibility and substrate utilization during submaximal exercise was evaluated 
via indirect calorimetry with a metabolic cart (TrueMax 2400®, Parvomedics, Inc., Sandy, UT) 
on a cycle ergometer (Corival Lode, Gronigen, The Netherlands). Before each measurement, the 
metabolic cart underwent both flow calibration using a 3-liter syringe and gas calibration using a 
standard gas concentration. Heart rate was monitored constantly throughout the test (Polar FT1, 
Polar USA, Port Washington, NY, USA). The first phase of the test was a warmup, where 
participants cycled at 0 watts for two minutes to adjust to experimental conditions and the cycle 
ergometer. Following the warmup, participants began exercise at 25 watts for two minutes, and 
wattage increased by 25 every two minutes until the participant reached 75% of HRR136. 
Participants were instructed to pedal at a rate of 60-80 revolutions per minute; RER, volume of 
oxygen update (VO₂), rate of perceived exertion (RPE), and heart rate will be recorded at the 
completion of each stage. Target exercise heart rate (THR) was calculated using the Karvonen 
equation prior to the submaximal exercise test using age-predicted maximal heart rate (MHR; 
Equation 7) and resting heart rate (RHR) using Equation 8. 
Equation 7: MHR = 220 – Age in years137. 
Equation 8: THR = ((MHR – RHR) 75% intensity) + RHR137. 
Data for each participant’s submaximal exercise test was exported in 15-second interval format 




Corporation, Redmond, WA, USA). Metabolic flexibility regarding substrate utilization was 
assessed by calculating and comparing the rates of fat oxidation (FATox), carbohydrate 
oxidation (CHOox), RER, and change in RER in the following intensity ranges, excluding the 
warm-up phase: 0-30% HRR (low intensity [LOW]), 31-50% HRR (moderate intensity [MOD]), 
and 50-75% HRR (high intensity [HIGH]). Oxidation rates for fat (LOWFATox, MODFATox, 
HIGHFATox) and carbohydrates (LOWCHOox, MODCHOox, HIGHCHOox) were calculated using the 
stoichiometric equations described by Jeukendrup47 using equations 9-11. Total FATox and 
CHOox were calculated by taking the sum of the oxidation rates multiplied by the time intervals. 
To assess overall metabolic flexibility, change in RER was calculated by subtracting RERREST 
from mean RER per intensity (ΔRERLOW, ΔRERMOD, and ΔRERHIGH). 
Equation 9: FATox (g ∙ min−1) = 1.695VO2(L ∙ min
−1) − 1.701VCO2(L ∙
              min−1) 
Equation 10: CHOox (g ∙ min−1) for intensity < 50% = 4.344VO2(L ∙
              min−1) − 3.061VCO2(L ∙ min
−1) 
Equation 11: CHOox (g ∙ min−1) for intensity 50 − 75% = 4.210VO2(L ∙
             min−1) − 2.962VCO2(L ∙ min
−1) 
Questionnaires for Lifestyle Factors 
 
A health history questionnaire was used to determine health status and confirm absence 
of diseases and disorders that would alter metabolic health and/or interfere with the ability to 
perform submaximal exercise. To characterize physical activity, the International Physical 
Activity Questionnaire Short Form (IPAQ-SF)138 was used to quantify physical activity level and 
sedentary time. The PSQI93 was used to indicate sleep quality. The Diet History Questionnaire 




The North American Menopause Society (NAMS) Menopause Health Questionnaire140 was used 
to obtain information about gynecologic history (menopause status) and obstetrical history 
(number of children), which were used to help determine relationships between lifestyle factors 
and measurement outcomes (body composition, metabolism, etc.). 
Cardiometabolic Blood Markers 
 
Blood from a finger prick was collected into a capillary tube and analyzed for TC, 
triglycerides (TRG), HDL, non-HDL (nHDL), and low-density lipoprotein (LDL) (Alere 
Cholestech LDX® Analyzer, Abbott, Chicago, IL, USA). Fasting blood glucose (GLU) was 
measured via a glucometer and corresponding test strips (OneTouch Ultra, LifeScan, Inc., 
Milpitas, CA, USA).  
Estrogen and Progesterone 
 
Participants provided a 2.5-3.0 mL passive drool saliva sample for estrogen and 
progesterone concentration analyses that were stored in a -80° freezer until batch analysis was 
completed in duplicate using commercially available assays by the Biobehavioral Lab at UNC 
Chapel Hill (Salivary 17 β-Estradiol Enzyme Immunoassay Kit, Salimetrics, LLC, State College, 
PA, USA; Salivary Progesterone (P4) Enzyme Immunoassay Kit, Salimetrics, LLC, State 
College, PA, USA). Prior to each visit, participants will be asked to refrain from dental work for 
a minimum of 48 hours, and from brushing their teeth for at least 1 hour to prevent blood from 
contaminating the sample.  
Statistics 
 
 Age, height, weight, and BMI were compared between groups using one-way analyses of 
variance (ANOVAs) with Bonferroni post-hoc pairwise comparisons following statistical 




and VAT), muscle characteristics (mCSA, mCSA/m2, and corrected EI), metabolic outcomes 
(REE, resting RER, exercise RER values, exercise FAT and CHO oxidation rates, and total CHO 
and FAT oxidized), hormones (estradiol and progesterone), cardiometabolic blood markers (TC, 
TRG, HDL, nHDL, LDL, and GLU), and survey outcomes (IPAQ-SF, PSQI, and DHQIII) were 
analyzed initially by conducting analyses of covariance (ANCOVAs) covaried for age with post-
hoc pairwise comparisons with Bonferroni adjustments if statistical significance was produced 
from the omnibus ANCOVAs. If the post-hoc pairwise comparisons indicated statistical 
significance from the initial ANCOVA, subsequent ANCOVAs were conducted covarying for 
age, estradiol, and progesterone. Bivariate Pearson’s correlations were used to determine 
associations between %fat and number of pregnancies, physical activity, number of menopause 
symptoms, dietary macronutrient intake, and years since menopause in the POST group. 
Bivariate Pearson’s correlations were also used to determine associations between FFM and 
dietary macronutrient intake. Results will be considered statistically significant if the p-value 
was below the alpha-level that was set to 0.05 a priori. All statistical tests were conducted using 







CHAPTER IV: MANUSCRIPT I 
METABOLIC EFFECT OF MENOPAUSE: A CROSS-SECTIONAL 
CHARACTERIZATION OF BODY COMPOSITION AND EXERCISE METABOLISM 
1 
Introduction 
 Forty-six million women in the United States were projected to be menopausal by 
20201,7. With the average age of menopause being 51 years, and life expectancy continually 
rising, women can spend up to 40% of their lives in the post-menopausal stage1. Menopause is 
the natural transition through which a woman’s ovaries shrink and reduce the production of 
ovarian hormones estrogen and progesterone, ultimately eliminating reproductive capabilities. 
The lengthy transition to menopause takes on average two to eight years, and is characterized by 
erratic hormone fluctuations, increased frequency of vasomotor symptoms, and accelerated 
changes in body composition beyond what would be expected from aging84,141,142. A recent study 
found that the direct cost of managing menopausal symptoms for approximately seven to ten 
years was about the same, and in some cases more expensive, as treating other diseases that are 
common among menopausal women (i.e., hypertension, mood disorders, anxiety, diabetes, 
osteoporosis, etc.)143,144. Ultimately, the burden of this transition, characterized as peri-
menopause, is associated with decreased quality of life, productivity, and potentially hindered 
personal and intimate relationships143.  
 




Some of the earliest investigations into the relationship between ovarian hormones, 
menopause, and body composition date back to the 1980s, documenting the role of estrogen in 
the regulation body composition and metabolism8. The first use of a 4-compartment (4C) 
criterion model (fat, protein, mineral, and water) to measure body composition was employed in 
1996, and reported that menopause was associated with increased fat mass (FM), decreased 
protein, decreased bone mass, and decreased body water49. A recent longitudinal study was able 
to identify accelerated rates of FM gain, coupled with a linear LM loss during the menopause 
transition15. The effects of menopause on changes in fat-free mass (FFM) and LM are 
inconclusive, with some studies reporting accelerated losses18,55, and others reporting no 
significant impact attributable to menopause12,49,57,142. Additionally, menopause is associated 
with a shift in fat distribution toward central obesity12,58,59, and one study reported nearly 50% 
more intra-abdominal fat in post-menopausal (POST) women compared to pre-menopausal 
women (PRE)57. Menopause also appears to induce accelerated rates of bone loss85,113,145, so it is 
important to employ methodologies capable of accounting for bone when studying menopausal 
women (i.e., dual-energy x-ray absorptiometry [DXA] and 4C models). It is also important to 
note that other data relevant to body composition and functionality such as muscle characteristics 
(i.e., muscle size and quality) in women traversing the menopause transition (i.e., peri-
menopausal women [PERI]) are still scarce. Understanding this transition and the concomitant 
changes in body composition is essential for disease prevention among mid-life women. 
Despite the prevalence and physiological impact of menopause, little is known about its 
influence on metabolism, specifically resting energy expenditure (REE) and metabolism during 
exercise. It is well-known that energy expenditure during rest and exercise is reduced with age10, 




and substrate utilization during exercise (i.e., metabolic flexibility). In existing literature, it is 
evident that menopause reduces total energy expenditure (TEE), but the effects of menopause on 
REE are inconclusive. Some evidence suggests that menopause may negatively impact REE, as 
one study observed a curvilinear downward trend in women ages 51-81 years compared to a 
linear decrease in women ages 18-50 years41. However, other studies have reported no 
significant differences attributable to menopause11,12. Additionally, studies investigating the role 
of ovarian hormones in PRE women and animal models have reported that higher estrogen levels 
may promote fat oxidation, which could have important implications for metabolism and body 
composition through menopause, and potentially exercise34,146.  
Since nearly all women living past approximately 50 years of age will experience 
menopause, it is imperative to find strategies that reduce the increased risk of chronic disease 
that accompanies menopause. While the regulatory roles of estrogen on metabolism, body 
composition, and bone health at the physiological level are relatively well-documented, research 
in women at all stages of menopause that ties together translational elements of metabolism, 
body composition, and lifestyle factors is lacking. Furthermore, the majority of research on this 
topic lacks all groups of women (i.e., PRE, PERI, and POST) or uses technologically inferior 
methods of measuring body composition (i.e., DXA alone, 2-compartment models) as opposed to 
a 4C criterion model, which is able to account for changes in bone and total body water (TBW). 
Lifestyle factors such as dietary habits, physical inactivity, and sleep may be important 
contributors to changes in body composition and metabolism, and therefore need to be evaluated 
regarding their interplay with menopause and chronic disease risk20. Therefore, the purpose of 
this study was to comprehensively evaluate body composition derived from a 4C criterion model, 




women at all stages of the menopause transition. A secondary aim was to identify relationships 




 Seventy-eight women were enrolled in this cross-sectional study (Figure 2); 6 dropped 
out prior to data collection due to time constraints. Data were analyzed for 72 female participants 
(Table 2). Of the total sample, 24 were pre-menopausal (PRE), 24 were peri-menopausal (PERI), 
and 24 were post-menopausal (POST). Women were considered PRE if they were still 
experiencing regular monthly periods (eumenorrheic) for the previous 12 months, PERI if they 
were experiencing irregular menstrual cycles (i.e., frequency, period length, flow changes) and 
were at least 38 years old, and POST if they had not had a period for 12 consecutive months. 
Menopausal status was also determined using Section 6 of the Menopause Health Questionnaire 
from The North American Menopause Society147 published for clinical use and obtaining 
information about menopause status. Age inclusion criteria was 35-60 years old, and we aimed to 
enroll an equal number of normal weight (body mass index [BMI] 18.5-24.9 kg/m2) and 
overweight/obese (BMI 25.0-39.9 kg/m2) in each of the PRE, PERI, and POST groups. Efforts 
were made to recruit a diverse sample of women, and racial/ethnic diversity per group is reported 
in Table 2.   
A health history questionnaire was used to determine health status and confirm absence 
of diseases and disorders that would alter metabolic health and/or interfere with the ability to 
perform submaximal exercise. Potential participants were excluded if they were currently 
pregnant, planning to become pregnant, currently nursing, or had a child in the previous 6 




self-reported BMI outside of the 18.5-39.9 kg/m2 range, were diagnosed with metabolic disease 
or disease that may alter body water (cardiovascular disease, diabetes [Type 1 or Type 2], renal 
disease), consumed metabolism altering drugs or medications outside of hormone replacement 
therapy (i.e., stimulants, insulin, phytoestrogens), were diagnosed with polycystic ovary 
syndrome (PCOS), or if they were competitive athletes (i.e., >200 min/week of vigorous exercise 
and/or >4 days/week of resistance training). Participants were weight-stable (had not gained/lost 
more than 5kg in the previous 2 months) and did not have musculoskeletal diseases or injuries 
within the prior 3 months or any contraindications to exercise. If participants were consuming 
medications for anxiety, depression, and/or thyroid conditions and had a medication change (i.e., 
dose, frequency, drug) within the previous 9 months, they were excluded. A summary of 
medication use can be found in Table 3. All procedures in this study were approved by the 
University’s Institutional Review Board in concordance with the Declaration of Helsinki, and all 
participants provided written informed consent prior to data collection. 
Experimental Design and Protocol 
 
 In a cross-sectional design, each participant completed one testing session. The in-person 
testing visit consisted of body composition and metabolic assessments, while the surveys were 
completed prior to the in-person visit at the participants’ convenience. Pre-menopausal women 
were tested within 7 days of the onset of menstruation, which was confirmed through self-
reported tracking of the menstrual cycle. Peri-menopausal women were tested at their earliest 
convenience if it had been 2 or more months since their last period; if still having relatively 
normal monthly periods, they were tested within 7 days of the onset of menstruation. Post-
menopausal women were tested at their earliest convenience. All testing visits occurred in the 




48 hours prior, and caffeine and alcohol for 12 hours prior to their visit130,131. Upon arrival, 
hydration status was confirmed via urine specific gravity assessment (USG: 1.002-1.025) and a 
urine pregnancy test for pre- and peri-menopausal women was used to confirm a negative 
pregnancy status. Height was measured via stadiometer (Perspective Enterprises, Portage, MI, 
USA), and weight was measured to the nearest 0.01 kg via a calibrated scale (Tanita Inc., Tokyo, 
Japan). Participants then underwent REE assessment followed by body composition assessments 
and a submaximal exercise.  
Body Composition  
4-Compartment Model 
Body composition was assessed using the 4C model described by Wang et al.128 to 
determine %fat, FM, and FFM using equations 1-3 where BV= body volume, TBW= total body 
water, Mo= total body bone mineral content, and BM= body mass. 
Equation 1: FM (kg) = 2.748 (BV) – 0.699 (TBW) + 1.129 (Mo) – 2.051 (BM). 
Equation 2: %fat = (FM/BM) x 100. 
Equation 3: FFM (kg) = BM – FM. 
Total body water was determined from bioelectrical impedance spectroscopy (BIS; 
SFB7, ImpediMed, Queensland, Australia); air displacement plethysmography (ADP; BodPod®, 
COSMED USA, Inc. Concord, CA, USA) to estimate BV, and a full-body DXA (GE Lunar 
iDXA, GE Medical Systems Ultrasound & Primary Care Diagnostics, Madison, WI) scan was 
used to measure total bone mineral content (BMC; Mo = BMC x 1.0436)128. Test-retest 
reliability for the 4C model in our laboratory is as follows: FM: intraclass correlation (ICC) = 




2.30 kg; %fat: ICC = 0.982%, SEM = 0.960%, and MD = 2.6%; FFM: ICC = 0.996 kg; SEM = 
0.999 kg, and MD = 2.75 kg. 
Dual-Energy X-Ray Absorptiometry 
 A whole-body DXA scan was utilized to obtain total body BMC to calculate Mo in the 
4C model. Participants wore lightweight athletic clothing and were asked to remove all metal, 
thick clothing, and heavy plastic to reduce interference with the scan. Participants laid supine in 
the center of the scanning table, and Styrofoam boards were placed between the hands and hips 
to retain a consistent distance between the trunk and arms. To standardize foot position, 
Styrofoam boards were also securely strapped to the participant’s feet in a dorsiflexed position. 
The scans were automatically analyzed by the software (encore Software Version 16), but 
specific regions of interest were confirmed by the technician. Bone mineral content was obtained 
from this scan and multiplied by 1.0436 to determine Mo for the 4C criterion model. Android to 
gynoid (AG) fat distribution recorded as a ratio, BMC, bone mineral density (BMD), and z-
scores were recorded and analyzed. In our laboratory, the test-retest reliability for DXA is as 
follows: FM ICC= 0.99, SEM= 0.46 kg, and %fat ICC= 0.99, SEM=0.81%. 
Bioelectrical Impedance Spectroscopy 
 A multi-frequency bioelectrical impedance device was used (SFB7 ImpediMed, 
Queensland, Australia [10 – 500 kHz]) to assess TBW, intracellular fluid content (ICF), and 
extracellular fluid content (ECF). This method has been previously validated against 
deuterium148,149. Participants removed metal, shoes, and their right sock to prevent interference 
with the measurement. Participants laid supine on a table with arms separated from the torso and 
enough space between the legs to ensure no contact. Two electrodes were placed 5 cm apart on 




the one 5 cm away, proximal to the third metacarpal-phalangeal joint. Two electrodes were 
placed on the dorsal side of the right ankle and foot: one on the malleoli, and one 5 cm away, 
proximal to the third metatarsal-phalangeal joint. Skin was cleaned with an alcohol swab prior to 
electrode placement to ensure contact and conductivity. Prior to testing, height, weight, age, and 
sex were entered into the device. Device software automatically estimated TBW, ICF, and ECF, 
and the average of two trials was recorded for the TBW, ICF, and ECF measurements. In our 
laboratory, previous data from BIS TBW measures have demonstrated high test-retest reliability: 
ICC= 0.99, SEM=0.93 L150.  
Air Displacement Plethysmography 
 
 To obtain the BV estimate used in the 4C model, ADP was used (BodPod®, COSMED 
USA, Inc., Concord, CA, USA). Prior to each BV measurement, the ADP device was calibrated 
according to manufacturer guidelines. In a private room, participants were asked to put all hair 
under a swim cap and wore tight-fitting clothing including compression shorts and sports bra. 
Participants were asked to remove all jewelry, watches, and glasses prior to measurement in 
order to reduce impacts of isothermal air. Body mass was measured to the nearest 0.01 kg using 
the software’s corresponding scale. Subjects were asked to sit upright in the BodPod®, to 
breathe normally, and to minimize movement. Body volume was measured at least twice, with 
measurements required to be within 150 mL of each other. If measurements were not within 150 
mL within each other, the measurement was repeated.  Thoracic gas volume was estimated 
according to manufacturer guidelines using the standard prediction equation, which previous 




Waist to Hip Ratio 
 Waist and hip circumferences were measured to the nearest 0.1 cm using a flexible 
inelastic plastic tape measure with a Gulick attachment while the participant stood with equal 
weight on each leg with their feet approximately 20 centimeters apart133. Waist circumference 
was measured at the smallest point between the lower rib and iliac crest parallel to the floor133. 
Hip circumference was measured at the level of the widest circumference over the buttocks133. 
Two trials were performed for each measurement, and if the results were within 1 centimeter, the 
numbers were averaged. If the two trials were not within 1 centimeter, measurements were 
repeated. Waist to hip ratio (WHR) was calculated as waist circumference (cm) divided by hip 
circumference (cm)133.  
Visceral Adipose Tissue 
 
Visceral adipose tissue (VAT) was measured via brightness (B)-mode ultrasound (Logiq-
e, GE Healthcare, Wisconsin, USA) using a curvilinear probe (GE: C1-5 RS) and standardized 
settings (Frequency: 4.0 MHz, Gain: 45)129. The probe was placed approximately 5 cm proximal 
to the umbilicus, and an image was captured when the participant fully exhaled. Visceral adipose 
tissue was then quantified by measuring the perpendicular distance from the interior border of 
the rectus abdominus and the posterior wall of the aorta 153,154. Two measurements were recorded 
and averaged. In our laboratory, test-retest reliability for VAT is as follows: ICC=0.99, SEM= 
0.35 cm, and MD= 0.69155.  
Muscle Characteristics 
 
Muscle characteristic measures of the vastus lateralis (VL) were determined using a B-
mode ultrasound (Logiq-e, GE Healthcare, Wisconsin, USA) from panoramic scans taken at the 




while the subjects laid supine with the right leg extended and relaxed on the examination table. 
To measure muscle cross-sectional area (mCSA) and echo intensity (EI), the technician 
performed a panoramic scan at 50% of the length of the femur. A correction factor for 
subcutaneous thigh fat thickness (THfat), previously described by Young et al.132, was used to 
account for the influence THfat has on EI measures (Equation 4), where y1 = raw EI, x =THfat, 
cf = 40.5278, and EIC = corrected EI.  
Equation 4: EIC (a.u.) = y1 + (x * cf). 
Subcutaneous THfat was determined by a linear measure from the epidermal layer to the fascial 
border of the VL taken at the distal, medial, and lateral sites and averaged132. Muscle cross-
sectional area was adjusted for body size by dividing mCSA by height in m2 156. All measures 
were analyzed using Image-J software (NIH, Bethesda, MD) by the same research technician. 
Reliability of mCSA and EI in the present study is as follows: mCSA ICC= 0.99, SEM= 0.43 
cm2; EI ICC= 0.99, SEM= 0.41 a.u.  
Metabolic Measurements 
Resting Energy Expenditure 
 Resting energy expenditure and substrate utilization were evaluated using a ventilated 
canopy with indirect calorimetry. Before each measurement, the metabolic cart underwent flow 
calibration using a 3-liter syringe and gas calibration using a standard gas concentration. For 30 
minutes (with the first 5 minutes discarded), subjects laid supine, while respiratory gases, oxygen 
uptake, and carbon dioxide production were analyzed over 15-second intervals with a metabolic 
cart (TrueOne 2400, Parvomedics, Inc., Sandy, UT, USA). Participants wore a heart rate monitor 




resting heart rate (RHR). Resting energy expenditure and respiratory exchange ratio (RERREST) 
were determined in kcals/day and a.u. using Equation 5134 and Equation 6135, respectively:  
Equation 5: REE (kcal/min) = [(3.9 ∗ (VO2(L∗min
−1))) + (1.1 ∗
              VCO2(L∗min
−1)))] ∗ 1,440 min. 




Reliability for REE and RERREST in our laboratory are as follows: REE ICC= 0.94, SEM= 125.6 
kcals, MD= 224.3 kcals; RER ICC= 0.83, SEM= 0.03, MD= 0.05 a.u. 
Metabolic Flexibility 
 
Metabolic flexibility and substrate utilization during submaximal exercise were evaluated 
via indirect calorimetry with a metabolic cart (TrueMax 2400®, ParvoMedics, Salt Lake City, 
UT, USA) on a cycle ergometer (Corival Lode, Gronigen, The Netherlands). Heart rate was 
monitored continuously throughout the test using a heart rate monitor chest strap. The first phase 
of the test was a warm-up, during which participants cycled at 0 watts for two minutes to adjust 
to experimental conditions and the cycle ergometer. Following the warmup, wattage increased by 
25 watts every two minutes until the participant reached 75% of their heart rate reserve (HRR), a 
submaximal exercise protocol similar to the one outlined by Pourhassan et al.136. Heart rate 
reserve was calculated using the Karvonen equation prior to the start of the test (Equations 7 and 
8)136,137: 
Equation 7: Age-predicted maximal heart rate (MHR)= 220-age. 
Equation 8: Target heart rate= ((MHR - RHR) * 0.75) + RHR. 
Participants were instructed to pedal at a rate of 60-80 revolutions per minute. Data for 
each participant’s submaximal exercise test was exported in 15-second interval format and 




Corporation, Redmond, WA, USA). Metabolic flexibility regarding substrate utilization was 
assessed by calculating and comparing the rates of fat oxidation (FATox), carbohydrate 
oxidation (CHOox), RER, and change in RER in the following intensity ranges, excluding the 
warm-up phase: ≤30% HRR (low intensity [LOW]), 31-≤50% HRR (moderate intensity 
[MOD]), and 51-75% HRR (high intensity [HIGH]). Oxidation rates for fat (LOWFATox, 
MODFATox, HIGHFATox) and carbohydrates (LOWCHOox, MODCHOox, HIGHCHOox) were calculated 
using the stoichiometric equations described by Jeukendrup47 using equations 9-11. Total FATox 
and CHOox were calculated by taking the sum of the oxidation rates multiplied by the time 
intervals. To assess overall metabolic flexibility, change in RER was calculated by subtracting 
RERREST from mean RER per intensity (ΔRERLOW, ΔRERMOD, and ΔRERHIGH). 
Equation 9: FATox (g ∙ min−1) = 1.695VO2(L ∙ min
−1) − 1.701VCO2(L ∙
              min−1). 
Equation 10: CHOox (g ∙ min−1) for intensity < 50% = 4.344VO2(L ∙
              min−1) − 3.061VCO2(L ∙ min
−1). 
Equation 11: CHOox (g ∙ min−1) for intensity 50 − 75% = 4.210VO2(L ∙




Participants provided a 2.5-3.0 mL passive drool saliva sample for estrogen and 
progesterone concentration analyses that were stored in a -80° freezer until batch analysis was 
completed in duplicate using commercially available assays by the Biobehavioral Lab at UNC 
Chapel Hill (Salivary 17 β-Estradiol Enzyme Immunoassay Kit, Salimetrics, LLC, State College, 
PA, USA; Salivary Progesterone (P4) Enzyme Immunoassay Kit, Salimetrics, LLC, State 




a minimum of 48 hours, and from brushing their teeth for at least 1 hour to prevent blood from 
contaminating the sample.  
Cardiometabolic Markers 
 
Blood from a finger prick was collected into a capillary tube and analyzed for total 
cholesterol (TC), high-density lipoprotein (HDL), non-HDL (nHDL), low-density lipoprotein 
(LDL), and triglycerides (TRG), (Alere Cholestech LDX® Analyzer, Abbott, Chicago, IL, 
USA). Fasting blood glucose (GLU) was measured via a glucometer and corresponding test 
strips (OneTouch Ultra, LifeScan, Inc., Milpitas, CA, USA).  
Surveys 
Physical activity was characterized using the International Physical Activity 
Questionnaire Short Form (IPAQ-SF)138 to quantify physical activity level (metabolic equivalent 
[MET]-minutes/week) and sedentary time (minutes/week). An additional question about number 
of days in the previous week that included structured resistance training with weights, 
bodyweight exercise, bands, or moving heavy objects repeatedly was added to quantify 
resistance exercise frequency. The Pittsburgh Sleep Quality Index (PSQI)93 was used to indicate 
sleep quality. The Diet History Questionnaire (DHQIII)139 was used to assess dietary habits, 
macronutrient consumption, and calorie intake; more specifically, settings included intake for the 
past 30 days without portion sizes. The North American Menopause Society (NAMS) 
Menopause Health Questionnaire147 was used to obtain information about gynecologic history 
(menopause status) and obstetrical history (i.e., number of children). 
Statistical Analyses 
 
 Age, height, weight, and BMI were compared between groups using one-way analyses of 




significance from the omnibus ANOVA. Body composition outcomes (4C, DXA, BIS, WHR, 
and VAT), muscle characteristics (mCSA, mCSA/m2, and corrected EI), metabolic outcomes 
(REE, resting RER, exercise RER values, exercise FAT and CHO oxidation rates, and total CHO 
and FAT oxidized), hormones (estradiol and progesterone), cardiometabolic blood markers (TC, 
TRG, HDL, nHDL, LDL, and GLU), and survey outcomes (IPAQ-SF, PSQI, and DHQIII) were 
analyzed initially by conducting analyses of covariance (ANCOVAs) covaried for age with post-
hoc pairwise comparisons with Bonferroni adjustments if statistical significance was produced 
from the omnibus ANCOVAs. If the post-hoc pairwise comparisons indicated statistical 
significance from the initial ANCOVA, subsequent ANCOVAs were conducted covarying for 
age, estradiol, and progesterone. Bivariate Pearson’s correlations were used to determine 
associations between %fat and number of pregnancies, physical activity, number of menopause 
symptoms, dietary macronutrient intake, and years since menopause in the POST group. 
Bivariate Pearson’s correlations were also used to determine associations between FFM and 
dietary macronutrient intake. Results will be considered statistically significant if the p-value 
was below the alpha-level that was set to 0.05 a priori. All statistical tests were conducted using 
SPSS (Version 26, IBM, Armonk, NY, USA). 
Results 
Participant Characteristics 
Omnibus one-way ANOVAs indicated statistical significance only for age (p=0.001). 
Age was significantly lower in PRE compared to PERI (Mean Difference [MD] ± Standard Error 
[SE]: -10.17 ± 0.98 yrs, p=0.001) and POST (MD ± SE:-15.29 ± 0.98 yrs, p=0.001); PERI was 
also significantly lower than POST (MD ± SE: -5.13 ± 0.98 yrs, p=0.001) (Table 2). Height, 




Reproductive Aging Workshop 2011157, 13 PERI women were classified as ‘early menopause 
transition’ (i.e., ≤ 60 days of amenorrhea since the last menstrual period), and were tested during 
the follicular phase of the menstrual cycle. There were 11 participants classified as ‘late 
menopause transition’ (i.e., >60 days since the last menstrual period but < 1 yr). In the POST 
group, 13 were identified as early post-menopause (i.e., <5 yrs since final menstrual period), and 
11 were identified as late post-menopause (i.e., >5 yrs since final menstrual period). 
Body Composition 
 For 4C outcomes, the omnibus ANCOVAs covaried for age indicated significance for 
FFM (p=0.003) and %fat (p=0.001). Post-hoc pairwise comparisons indicated no significant 
difference in FFM between groups (Table 4). In PRE, %fat was significantly lower than PERI, 
which was retained following additional covariation for estradiol and progesterone (covaried MD 
± SE: -9.94 ± 3.68%, p=0.026) (Table 4, Figure 3), while %fat was similar between PRE and 
POST (p=0.198) and PERI and POST (p=0.999) (Figure 3). Likewise, FM was not different 
between groups (p>0.05). Omnibus ANCOVAs covaried for age demonstrated similarity for all 
DXA outcomes between groups (p>0.05) except for AG ratio (p=0.011). Android to gynoid ratio 
was significantly lower in PRE than PERI, which was maintained following additional 
covariation for estradiol and progesterone (covaried MD ± SE: -0.21 ± 0.08 a.u., p=0.031) (Table 
4, Figure 4). For BIS outcomes, the omnibus ANCOVA covaried for age demonstrated 
significance for ICF (p=0.016), however, pairwise comparisons indicated no difference between 
groups (p>0.05) (Table 4). Extracellular fluid content, WHR, and VAT (Figure 5) were similar 





 For analyses of muscle characteristics, the omnibus ANCOVAs covaried for age 
indicated no significant differences in mCSA (cm2) (p=0.077), adjusted mCSA/m2 (a.u.) 
(p=0.325), and corrected EI (a.u.) (p=0.056) (Table 5, Figure 6).  
Metabolism 
Resting Metabolism 
Omnibus ANCOVAs covaried for age indicated no significant differences for REE 
(Figure 7) (p=0.130) and RERREST (p=0.054) (Table 6). 
Metabolic Flexibility 
Omnibus ANCOVAs covaried for age indicated no significant differences for 
submaximal test time, RERLOW, RERMOD, RERHIGH, ΔRERLOW, ΔRERHIGH, LOWFATox, 
HIGHFATox, LOWCHOox, MODCHOox, total FATox, total CHOox (P>0.05) (Table 6, Figure 8). The 
omnibus ANCOVA covaried for age indicated significance for MODFATox (p=0.030), with PRE 
experiencing significantly greater fat oxidation than POST (covaried MD ± SE: 0.10 ± 0.05 
g/min, p=0.045), however the subsequent omnibus ANCOVA covaried for estradiol and 
progesterone was not significant (p=0.067) (Table 6). The initial ANCOVA for HIGHCHOox 
indicated trending significance (p=0.050), however, post-hoc pairwise comparisons indicated no 
significant differences between groups. When assessing overall flexibility (ΔRER), the initial 
omnibus ANCOVAs indicated similarities in ΔRERLOW and ΔRERHIGH (p>0.05) and significant 
differences in ΔRERMOD (p=0.042), with PRE experiencing significantly lower ΔRER than PERI 
(covaried MD ± SE: -0.11 ± 0.04 a.u., p=0.035) and POST (covaried MD ± SE: -0.15 ± 0.06 a.u. 
p=0.04) (Table 6); this significance was no longer present in the subsequent ANCOVAs 




Hormones and Cardiometabolic Blood Markers 
The omnibus ANCOVAs covaried for age revealed no significant differences for salivary 
estradiol, salivary progesterone, nor any of the cardiometabolic blood markers (p>0.05) (Table 7, 
Figure 9). 
Surveys 
IPAQ-SF outcomes (MET-minutes/week, sitting time per workday, and number of lifting 
days/week [Figure 10]) were similar between groups following ANCOVAs covaried for age 
(p>0.05) (Table 8). Similarly, PSQI global sleep scores were indifferent between groups, as 
indicated by an ANCOVA covaried for age (p>0.05) (Table 8). DHQIII outcomes (energy intake 
[Figure 7], protein, carbohydrate, fat, fiber, and relative macronutrient kcal percentages of total 
intake) were similar, according to the omnibus ANCOVAs covaried for age (p>0.05) (Table 8). 
Omnibus ANCOVAs for NAMS Menopause Health Questionnaire outcomes indicated 
significance number of menopause symptoms (p=0.001), but not number of pregnancies 
(p>0.05). The ANCOVAs covaried for age analyses revealed significantly more menopause 
symptoms in PERI (covaried MD ± SE: 8.88 ± 2.43, p=0.001) and POST (covaried MD ± SE: 
8.09 ± 3.23, p=0.044) compared to PRE, however, PERI and POST were similar (p>0.05) (Table 
8, Figure 11). Statistical significance was retained in the subsequent ANCOVAs covaried for 
age, estradiol, and progesterone in that PERI experienced more menopause symptoms than PRE 
(covaried MD ± SE: 8.8 ± 2.49, p=0.002), however, significance was not retained in the PRE to 
POST comparison (p=0.061) (Table 8, Figure 11). An overview of the distribution of the top 10 
reported symptoms can be found in Table 9. 
Body fat percent was not significantly correlated with number of pregnancies (Pearson 




p=0.613), however, the correlation between %fat and number of menopause symptoms in PERI 
and POST females was significant (R=0.445, p=0.002). In the POST group, years since 
menopause was not significantly correlated to %fat (p=0.901). Relative energy intake expressed 
as a percentage of total intake from protein (EIPRO), carbohydrates (EICHO), and fat (EIFAT) were 
not significantly correlated to %fat (p>0.05). The correlation between FFM and EIFAT was not 
significant (p>0.05), while the positive correlation between FFM and EIPRO approached 
statistical significance (R=0.228, p=0.054); the inverse correlation between FFM and EICHO was 
statistically significant (R=-0.242, p=0.041).  
Discussion 
 Peri-menopause can be a lengthy and costly transition during which women experience 
accelerated changes in body composition and metabolism relative to the expected changes that 
occur with aging25,143. Little is known about shifts in body composition measured via detailed 
methodologies (i.e., 4C model), or metabolic flexibility from rest to exercise, which could play a 
role in the changes observed through menopause. Understanding these detailed changes may 
highlight an optimal time for preventative interventions. In this cross-sectional study of women 
throughout the menopause transition, we observed that despite similarities in anthropometric 
measures (i.e., height, weight, BMI), women in peri-menopause exhibited more unfavorable 
body composition traits (i.e., greater FM, lower FFM, and elevated %fat) compared to PRE and 
POST women. Moreover, measures of fat distribution indicated that PERI women experienced 
comparatively greater fat deposition in the abdominal region, with AG ratio in PERI being on 
average 16% higher than PRE and 5% higher than POST, with similar differences for VAT. 
Metabolism may have a direct relationship with body composition, as well as help to explain 




with POST having an average drop in REE of 116 kcal/day compared to PRE. At rest, PERI 
experienced the lowest RER (i.e., greatest fat oxidation), which presents an interesting paradox 
between body composition and metabolism during the menopause transition, however, it’s 
possible that this observation was influenced by estradiol levels. During exercise, metabolic 
flexibility and substrate utilization were similar at low and high intensities; however, the most 
notable differences were observed at the moderate intensity with the POST cohort experiencing a 
significantly lower fat oxidation rate of 0.20 g/min compared to 0.29 g/min in PRE (31% 
reduction). Furthermore, analyses of overall metabolic flexibility (i.e., change in RER from rest 
to exercise) during moderate intensity exercise indicated poorer flexibility in PERI and POST. 
Altogether, shifts in body composition and metabolism appear to peak during peri-menopause 
and stabilize in post-menopause. This data highlights peri-menopause as a critical window for 
interventions to prevent detrimental changes in body composition and metabolic health. 
 To our knowledge, this study is the first to employ a modern 4C criterion method to 
analyze body composition through the menopause transition with a cross-sectional approach. The 
present study reports that menopause is associated with greater FM, lower FFM, and 
consequently higher %fat, which is in concordance with presumably the first study to use a 4C 
model to understand women as they age49, as well as another cross-sectional study that utilized 
DXA158. More specifically, the study conducted by Aloia et al.49 reported that women aged 31-
40 years (likely pre-menopause) had approximately 4.5 kg lower FM than the 41-50 years group 
(likely peri-menopause), with the latter group reporting an average 0.9 kg greater FM compared 
to 51-60 years group (likely post-menopause). The present study found a similar trend in FM 
with 7.1 kg (23%) greater FM in PERI compared to PRE; FM on average was 1.4 kg (5%) lower 




changes based on the sensitivity of the 4C method. A cross-sectional study that utilized DXA to 
compare PRE (mean age 47 yrs) and early POST women (mean age 51 yrs) reported that FM 
was 28% higher in POST (MD ~5 kg), however, reported no differences in FFM57. The present 
study reported similar differences in FFM, with an average 6.1 kg lower FFM in PERI than PRE; 
the difference between PRE and POST was much smaller (0.12 kg), highlighting the potential 
importance of the perimenopause stage. Additionally, another study reported an average 2.7 
kg/decade decrease in lean mass from ages 40-60158, which translates to ~5.4 kg from PERI to 
POST, which aligns with the 5.9 kg difference in FFM observed in the present study. Higher FM 
and lower FFM identified in the present study in the PERI group produced a statistically 
significant higher %fat than PRE (10.3%), while POST reported 1.2% lower %fat than PERI. 
Toth et al.57 reported that %fat in early POST was on average 5% higher than PRE, which is a 
smaller difference likely as a result of the small age difference (~4 yrs) between their groups. 
Longitudinal studies have presented similar findings to the present study, with most reports 
suggesting accelerated FM gain during the menopause transition that exceeds age-related 
changes12,15, however, a large recent meta-analysis suggested that menopause may have a greater 
impact on fat distribution rather than FM at large58; longitudinal data regarding muscle mass 
remains inconclusive, with one study reporting decreases15 and another reporting no change12. 
 The 4C criterion model is also able to account for body water, a compartment that has not 
been extensively explored through the menopause transition, and may be the most variable due 
to changes in muscle mass and assumption in fat-free body density in more traditional body 
composition approaches159,160. The present study found that TBW decreased the most from PRE 
to PERI by 2.94 L, while POST was only slightly lower than PERI by 0.04 L. The one previous 




31-40 years group having similar body water to the 41-50 years group (0.1 L difference), 
however, the 51-60 years group reported 1.1 L lower TBW than the 31-40 years group49. The 
reduction in TBW observed may be due in part to decreased thirst sensitivity to alterations in 
central body fluid seen in aging women, as well as reduced estrogen levels, which are believed to 
impact osmotic sensitivity regarding maintenance of body water161. When assessing the 
distribution of TBW, it appears that the largest changes were observed in ICF: PRE was greater 
than PERI by 2.32 L, while POST was only 0.08 L lower than PERI; ECF was higher in PRE 
than PERI by 0.76 L, while PERI was greater than POST by a mere 0.04 L. The large 2.94 L 
drop in TBW, which equates to ~3 kg of water, attributed mostly to the shift in ICF observed 
between PRE and PERI, indicates the importance of including a measure of body water for 
improved accuracy when evaluating body composition through menopause. 
 Measures of fat distribution in the present study indicated heightened central adiposity in 
the PERI group, as this group had the greatest AG ratio, highest WHR, and greatest VAT. More 
specifically, DXA-measured AG ratio in the present study was significantly higher in PERI than 
PRE by 0.16 a.u. on average, which translated to a 16% difference, and remained statistically 
significant following adjustment for age, estradiol, and progesterone. A small difference was 
observed between PERI and POST, as POST was 0.05 a.u. lower (5% difference), further 
indicating that impacts of the menopause transition may partially subside once the transition is 
complete. We observed similar but not statistically significant trends in WHR and VAT, which 
are measurements that are more common in the literature. The PRE group had the lowest WHR 
(0.76 a.u.) while the PERI group had the highest (0.79 a.u.) and POST was 0.01 a.u. lower than 
PERI (0.78). A large cross-sectional study observed that over 80% of POST women (mean age 




group reached this WHR64. While the present study sample size is too small to run similar 
analyses, it is interesting to note that 50% of the women in the PERI group had WHR >0.80 a.u. 
while only 25% of PRE and POST groups reached this WHR cutoff. Longitudinal studies have 
failed to find a significant relationship between menopause status and waist circumference65,66, 
however, one study noted that waist circumference tended to become higher in women who 
became post-menopausal during the study65. Interestingly, some longitudinal studies have 
identified a relationship between menopause status and VAT12,62, while another observed an 
increase in VAT over time that was not dependent upon menopausal status63. Longitudinal 
studies have observed that POST had on average 8.6-9.5 cm2 more VAT (~10-20% change) than 
PRE women, which one group attributed to greater levels of bioavailable testosterone and 
consequently a male-patterned adiposity trend12,62. Cross-sectional data support similar findings: 
one study observed 50% greater intra-abdominal fat in early POST compared to PRE, while the 
present study reported 17% higher VAT in PERI compared to PRE (MD 0.83 cm), and 8% 
higher than POST (MD 0.41 cm)57. Taken together, data from the present study, other cross-
sectional studies, and longitudinal studies suggest that menopause likely influences fat 
distribution by increasing abdominal adiposity. Of note, further research should aim to include 
DXA-derived AG ratios as a measure of fat distribution when possible to minimize potential 
human error that may be associated with measuring WHR and VAT by hand. 
 Bone density changes with menopause are widely characterized, with an increased risk of 
osteopenia and osteoporosis in menopause84,85,162. From a whole body DXA scan, the present 
study found that PRE had the highest BMC and Mo while PERI had the lowest BMC (0.24 kg 
lower than PRE) and Mo, and POST had slightly higher BMC (0.05 kg) and Mo than PERI, 




previously mentioned observed equal mineral amounts in their 31-40 years and 41-50 years 
groups, but noted a 0.2 kg decrease in in the 51-60 years group.49 We observed similar trends for 
BMD and z-scores. BMD in PRE was 0.07 g/cm2 higher than PERI and 0.04 g/cm2 higher than 
POST (mean 1.23 g/cm2). One large cross-sectional study identified accelerated loss of BMD at 
the spine, hip, and radius between the ages of 50-59 years, indicating that menopause likely 
exacerbates normal bone loss that occurs with aging83. Furthermore, an extensive longitudinal 
study identified that the overwhelming majority of BMD loss occurred during a critical 3-year 
period falling one year prior to the final menstrual period through two years following the final 
menstrual period84. Therefore, our lack of statistical significance for downward shifts in bone 
outcomes is likely due to methodological limitations. Z-scores in PERI were 0.37 a.u. lower than 
PRE (41%) and 0.20 a.u. lower than POST (26%), indicating that our PERI group was slightly 
above the normative average (mean score 0.58), while our PRE group was nearly one standard 
deviation above average (mean score 0.98), and our POST group had an average z-score of 0.78. 
It’s possible that the POST group in the present study retained BMC, and had relatively high z-
scores due to having higher levels of physical activity (mean 1,078 MET-min/week greater than 
PRE)163.   
 Resting energy expenditure demonstrated a downward trend across the transition; PRE 
was on average 48 kcal/day higher than PERI and 116 kcal/day higher than POST (8% 
difference), while PERI was 68 kcal/day higher than POST. It is interesting to note that this 
downward trend occurred despite the upward trend in physical activity observed: PRE reported 
479 MET-min/week fewer than PERI, and 1,078 MET-min/week fewer than POST. It is possible 
that increased physical activity observed through the menopause transition in this study reduced 




the statistically nonsignificant comparisons39,164. An older cross-sectional study identified a 
period of accelerated decline in REE in women ages 51-80 years, with an estimated 4% rate of 
reduction per decade compared to the average 0.6% reduction observed in women ages 18-5041. 
Given that our POST group was on average 16 years older than PRE, our 8% observed 
difference is likely in line with the prediction suggested, indicating a potential effect of 
menopause on REE41. Additionally, a longitudinal study identified a 9% drop in sleeping energy 
expenditure in women who became post-menopausal during the study, further implying that our 
results may represent a meaningful trend despite the lacking statistical significance, especially 
considering the marked increase in physical activity12. In contrast, another longitudinal study 
identified a downward trend in total energy expenditure through the menopause transition, but 
this shift was mainly induced by decreased physical activity and not a change in REE38. While 
PRE and POST groups in the present study demonstrated similar values in RER at rest (mean 
0.76 a.u.), PERI exhibited greater fat oxidation (mean 0.73 a.u.). The difference between PRE 
and PERI (0.03 a.u.) approached statistical significance (p=0.076), and this finding was not 
entirely surprising given that PERI had elevated estradiol levels compared to PRE (17% higher); 
estradiol is believed to increase fat oxidation by increasing sensitivity to hormone sensitive 
lipase through the promotion of other hormones like catecholamines8,165. Similar changes in RER 
are observed throughout the normal menstrual cycle in eumenorrheic women146,166,167, and it is 
also important to note that this observed difference between PRE and PERI equals the SEM. Our 
hypothesis that fat oxidation would decrease through the menopause transition was not 
supported, however, these results were likely influenced by hormone variability in PERI as well 
as the upward trend in physical activity that may have supported greater fat oxidation at rest, 




 During low intensity exercise (≤30% HRR), PERI women demonstrated the greatest fat 
oxidation, as indicated by a lower RER than PRE (MD 0.04 g/min, 17% difference) and POST 
(MD 0.06 g/min, 25% difference), as well as the greatest carbohydrate oxidation. Differences 
observed at the low intensity may be in part due to variance in estradiol levels in PERI, as well as 
the PERI group reporting greater physical activity than PRE. We observed an interesting, yet 
expected, shift during moderate intensity exercise (31-≤50% HRR); fat oxidation in PRE was 
31% higher (MD 0.09 g/min) than POST, and 17% higher than PERI (MD 0.05 g/min). The 
comparison between PRE and POST was statistically significant after covarying for age alone, 
however, this significance was abolished following adjustment for estradiol and progesterone 
levels, suggesting that this difference in fat oxidation may be induced by hormonal changes as a 
result of menopause. One study that used a steady-state exercise protocol for 45 minutes at 50% 
VO2max noted that RER in POST women was 0.03 a.u. higher than PRE women
42. The same 
study reported 23% lower whole-body fat oxidation (MD 0.21 g/min) in POST women compared 
to PRE, which is similar to the 31% difference in fat oxidation observed in the present study, 
ultimately supporting a blunted oxidative capacity in menopause during moderate intensity 
exercise42.  These results suggest that peri-menopause incites metabolic inflexibility that is 
sustained into post-menopause. The disparity in RER between groups was smaller at the high 
intensity (51-75% HRR), as RER in PRE and PERI were equal, and only 0.02 a.u. lower than 
POST. Despite similarities in RER, the differences in fat and carbohydrate oxidation were 
noteworthy: POST had the lowest fat oxidation rate, which was 0.06 g/min (33%) lower than 
PRE and only 0.01 g/min (7%) lower than PERI. Carbohydrate oxidation rates followed a similar 
trend in that POST had an oxidation rate about 20% less than PRE and only 8% less than PERI. 




which translated to a reduction in total fat oxidation during the exercise bout by 37% in POST 
compared to PRE. This reduction does not appear to be mitigated by increased physical activity 
levels observed in the present study. In healthy adults, exercise training along with diet have 
been shown to impact metabolic flexibility and fat oxidation capacity during exercise43,44,169,170, 
however, total energy intake (kcal/day), macronutrient intake (protein, carbohydrates, fat; g/day), 
and macronutrient percentages of total intake (% energy from protein, carbohydrates, fat) were 
remarkably similar and not significantly different between groups in the present study. 
 Estradiol was unsurprisingly lowest in the POST group, but only about 7% lower (MD 
0.06 pg/mL) than PRE and 23% lower (MD 0.22 pg/mL) than PERI. The highest estradiol levels 
is a direct reflection of the hormone variability associated with PERI, and the associated drop in 
estradiol occurring late in the transition171,172. Some studies have reported that estradiol 
fluctuation in the luteal phase in PERI can reach levels that are twice as high as levels observed 
in the late follicular menstrual phase in PRE, as well as early follicular levels lower than what 
would normally be observed during this time in PRE women141,173. The reported range of the 
estradiol assay in the present study is 1-32 pg/mL, indicating that our samples (PRE [mean 0.85 
pg/mL], PERI [mean 1.02 pg/mL], POST [mean 0.79 pg/mL]) were in the lowest range of 
detectability, and that we were successful in testing women when estradiol levels were lowest. In 
eumenorrheic PRE women, progesterone levels rise following ovulation to prepare the body for 
pregnancy, so it is expected that as ovulation becomes less frequent in peri-menopause followed 
by cessation in post-menopause, progesterone levels would decline172. Our data reflects 
relatively low progesterone levels within PRE (mean ± SD: 50.79 ± 40.42 pg/mL), likely due to 
testing in the early follicular phase when hormone levels are low, as well as POST (mean ± SD: 




progesterone values with the greatest variance (mean ± SD: 73.68 ± 115.64 pg/mL), which could 
be due to the irregularity of, and lengthened menstrual cycles characteristic of peri-
menopause172. A review article reported that normal salivary progesterone levels during the 
follicular phase and luteal phase in eumenorrheic PRE women fall around 30 pg/mL and 100-200 
pg/mL, respectively174, again indicating that our participants were for the most part tested during 
the low hormone follicular phase. 
 It is important to characterize lifestyle factors that may influence measurement outcomes 
such as body composition and metabolism. In the present study, physical activity trended upward 
along with sedentary time through the menopause transition, although no comparisons were 
statistically significant. Our results were similar to another study that used a survey and found 
that women who became menopausal increased their physical activity, which authors attributed 
to increased motivation to prevent weight gain88. Change in activity might also be related to 
time, with more available time in POST life phase. In contrast, a longitudinal study that utilized 
accelerometry identified that physical activity energy expenditure was reduced by about 50% in 
menopausal women12. In the present study, the COVID-19 pandemic may have influenced 
results, with PRE and PERI women likely experiencing reduced physical activity and sedentary 
time due to the responsibility of monitoring young children175. Global sleep quality scores were 
similar in PERI and POST (MD 0.04), while PRE had slightly lower, but not significantly 
different scores (MD 1.21-1.25), which indicates slightly better sleep quality in PRE. Another 
study that used the PSQI demonstrated poorer sleep quality in POST women, with a downward 
linear trend in sleep quality through the menopause transition96. Women early in the menopause 
transition reported global scores of 4.90, which is slightly lower than the 5.08 score observed in 




reported mean scores of 5.65 and 6.39, respectively, which are similar to the reported values of 
PERI (mean 6.33) and POST (6.29) in the present study. When comparing ‘good’ sleepers (score 
≤ 5176) across groups, we found that 63% of PRE, 42% of PERI, and 33% of POST were 
identified as ‘good’ sleepers, which more closely follows the linear trend observed by Zhang et 
al.96.  
As previously mentioned, dietary outcomes were very similar between groups, with 
POST reporting slightly higher energy intake than PERI (MD 51 kcal/day). While there is 
considerable error associated with assessing diet via surveys, one study reported macronutrient 
percentages of total energy intake to be the most viable outcomes for comparisons177. When 
comparing relative percentages attributed to protein, carbohydrates, and fat intake, all groups in 
the present study reported means that were within about 2% of each other. This data contrasts 
observations from other studies indicating that energy intake and carbohydrate intake both 
decreased, coupled with increased fat consumption following the menopause transition12,91. The 
correlative relationships observed in the present study between FFM and EIPRO (positive 
relationship) combined with FFM and EICHO (negative relationship) indicates that a higher 
protein, lower carbohydrate diet may help retain lean mass through the menopause transition. 
Regarding number of menopause symptoms reported (30 possible options), it was unsurprising 
that PERI indicated the highest number of symptoms compared to PRE (MD 6.58 symptoms), 
which retained statistical significance following adjustment for age and hormones. Number of 
symptoms reported by PERI was also significantly higher than POST (MD 4.64 symptoms), 
which was only statistically significant after adjustment for age but not hormones, indicating a 
potential influence of menopause. The most common symptoms reported at least ‘a little bit’ in 




concentrating. In PERI, 78% of participants selected at least ‘a little bit’ for increased tiredness, 
poor memory, lack of desire or interest in sexual activity, and stomach feeling bloated or weight 
gain. In POST, 75% of participant selected at least ‘a little bit’ for vaginal dryness, stomach 
feeling bloated or weight gain, and joint pains. A statistically significant positive correlation 
indicated that as %fat increased, number of symptoms increased, which coincides with another 
study that reported obesity is associated greater vasomotor symptoms, particularly in PERI and 
early POST women178.  
While the present study provided a comprehensive cross-sectional evaluation across the 
menopause transition, there are limitations associated with cross-sectional study designs. 
Longitudinal studies may have more statistical power to detect minute changes over time in one 
group of participants, however, they are usually more costly, have potential for higher drop-out 
rates, and are time intensive with the menopause transition spanning an average of 2-8 years179. 
The majority of longitudinal literature assessing body composition through menopause has used 
DXA, a 3-compartment model, indicating the necessity for a study using more detailed 
methodology (i.e., 4C model). Due to time and scheduling constraints, it is possible that some 
PERI women were tested when unpredictable hormone fluctuations were occurring, which may 
have induced some of the variability observed in hormone levels and lower RER values at rest. 
Additionally, there was a wide age range in PERI participants (41-57 yr), however, covarying for 
age should have helped to mitigate this limitation. The present study had exercise inclusion 
criteria of <200 min/week of vigorous intensity exercise and/or <4 days/week of resistance 
training, which may not have been strict enough to ensure homogenous physical activity levels 
between groups. Moreover, there is error associated with assessing physical activity and diet via 




provide a comprehensive overview that encompassed lifestyle characteristics of the participants. 
We believe the cross-sectional data obtained in the present study provides important comparative 
data at different intensity levels across menopausal groups, which no other studies to our 





CHAPTER V: CONCLUSION 
 
 In the present cross-sectional study of women through the menopause transition, we 
observed that peri-menopause may be the most opportune window for lifestyle intervention, as 
this group experienced elevated %fat, lower FFM, and a shift toward central obesity despite 
similarities between anthropometric and diet outcomes. The greatest changes in %fat and AG 
ratio were observed from PRE to PERI, indicating that the menopause transition likely stimulates 
the changes that are followed by stabilization in post-menopause. The greatest differences in 
exercise metabolism were highlighted during moderate intensity exercise, with POST displaying 
the poorest metabolic flexibility (i.e., lowest substrate oxidation rates, greatest change in RER), 
while PERI did not sustain the comparatively lower RER values that were observed at rest. RER 
during moderate intensity was 0.02-0.06 a.u. greater in PERI and POST than PRE, which was 
not statistically significant but clinically relevant. It is interesting to note that these differences in 
exercise metabolism occurred despite greater average physical activity reported in PERI and 
POST groups. To prevent unwanted changes in resting metabolism as well as metabolic 
flexibility, it is possible that menopausal women should engage in activities that help maintain 
lean mass (i.e., resistance exercise) as well as retain or increase oxidative capacity (i.e., moderate 
to high intensity exercise180). Ultimately, future cross-section investigations and longitudinal 
interventions should be designed to target PERI women to determine if menopause-related shifts 






Table 1. Summary of hormonal changes throughout menopause.  
Variable 
Reference      
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Table 2. Subject anthropometric characteristics. Data are presented as mean ± standard deviation for 
anthropometrics, racial distribution, and BMI distribution across groups. Statistical significance 
(p<0.05) is indicated by *. 
 Age (yrs) Height (cm) Weight (kg) BMI (kg/m2) 
Total Sample 
(n=72) 
48.28 ± 7.21 163.03 ± 6.34 69.21 ± 14.21 26.05 ± 5.21 
PRE (n=24) 39.79 ± 3.27* 165.12 ± 5.75 68.95 ± 14.61 25.25 ± 5.06 
PERI (n=24) 49.96 ± 3.37* 162.56 ± 7.00 69.96 ± 15.18 26.48 ± 5.44 
POST (n=24) 55.08 ± 3.49* 161.42 ± 5.92 68.72 ± 13.36 26.42 ± 5.24 
Race PRE PERI POST 
White 12 17 15 
Black 5 2 6 
Hispanic 3 5 2 
Asian 3 - 1 
Mixed Race 1 - - 
BMI    
BMI 18.5-24.9 
(kg/m2) 
13 12 11 
BMI ≥25.0 
(kg/m2) 










Table 3. Subject medication use for hormone replacement therapy, anxiety, depression, birth 
control, and thyroid disorders. 
 PRE PERI POST 
Hormone Replacement Therapy 
Estrogen (patch) 
Progesterone (pill or tablet) 






























































Pill, Ring, or Skin Patch 







































Table 4. Descriptive statistics for body composition outcomes. Dara are presented in the PRE, PERI, and POST columns as mean 
± standard deviation (SD). Raw data for comparisons between groups in the following columns are presented as mean difference 
(MD) ± standard error (SE) and calculated as PRE-PERI, PRE-POST, and PERI-POST. Statistical significance from ANCOVAs 
covarying for age, estradiol, and progesterone (p<0.05) is indicated by † with corresponding p-values. Reported p-values are from 
ANCOVAs covarying for age unless significance was retained following further covariation for estradiol and progesterone. 












4C Model           
FM (kg) 20.19 ± 10.59 26.37 ± 10.66 25.00 ± 9.10 -7.07 ± 3.10 0.217 -5.71 ± 3.10 0.564 1.37 ± 3.10 0.999 
FFM (kg) 49.67 ± 7.02 43.60 ± 6.46 43.71 ± 5.82 6.06 ± 1.86 0.817 5.94 ± 1.86 0.999 -0.12 ± 1.86 0.999 
%fat (%) 27.89 ± 8.20 36.60 ± 8.00 35.43 ± 7.00 
-10.29 ± 
2.73† 
0.026 -9.11 ± 2.73 0.198 1.17 ± 2.73 0.999 
BMC (kg) 2.53 ± 0.36 2.29 ± 0.27 2.34 ± 0.44 0.24 ± 0.10 0.999 0.19 ± 0.10 0.999 -0.05 ± 0.10 0.730 
Mo (kg) 2.64 ± 0.38 2.39 ± 0.28 2.44 ± 0.46 0.25 ± 0.11 0.999 0.20 ± 0.11 0.999 -0.05 ± 0.11 0.730 
DXA          
BMD 
(g/cm2) 
1.27 ± 0.13 1.20 ± 0.10 1.23 ± 0.16 0.07 ± 0.04 0.999 0.04 ± 0.04 0.999 -0.03 ± 0.04 0.650 




0.83 ± 0.21 0.99 ± 0.13 0.94 ± 0.15 
-0.16 ± 
0.05† 
0.031 -0.11 ± 0.05 0.305 -0.05 ± 0.05 0.999 
Z-score 0.98 ± 0.75 0.58 ± 0.86 0.78 ± 1.23  0.39 ± 0.30 0.999 0.20 ± 0.30 0.999 -0.20 ± 0.30 0.999 
BIS          
TBW (L) 35.79 ± 5.10 32.85 ± 5.10 32.80 ± 4.68 2.94 ± 1.43 0.999 3.00 ± 1.43 0.999 0.04 ± 1.43 0.999 
ECF (L) 14.53 ± 2.02 13.77 ± 2.17 13.73 ± 1.88 0.76 ± 0.59 0.999 0.80 ± 0.59 0.999 0.04 ± 0.59 0.999 
ICF (L) 21.39 ± 3.42 19.07 ± 3.02 18.99 ± 2.66 2.32 ± 0.88 0.999 2.40 ± 0.88 0.999 0.08 ± 0.88 0.999 
WHR 
(a.u.) 
0.76 ± 0.05 0.79 ± 0.05 0.78 ± 0.05 -0.03 ± 0.01 0.999 -0.02 ± 0.01 0.999 0.01 ± 0.01 0.925 








Table 5. Descriptive statistics for muscle characteristics outcomes. Dara are presented in the PRE, PERI, and POST columns as 
mean ± standard deviation (SD). Raw data for comparisons between groups in the following columns are presented as mean 
difference (MD) ± standard error (SE) and calculated as PRE-PERI, PRE-POST, and PERI-POST.  














18.70 ± 3.80   17.17 ± 4.70  15.70 ± 3.70  1.53 ± 1.18  0.999 3.00 ± 1.18  0.999 1.47 ± 1.18 0.999 
mCSA/m2 
(a.u.) 

























Table 6. Descriptive statistics for metabolic outcomes. Data are presented in the PRE, PERI, and POST columns as mean ± 
standard deviation (SD). Number of participants per intensity per group are as follows: LOW intensity (PRE=23, PERI=18, 
POST=19), MOD intensity (PRE=24, PERI=24, POST=22), and HIGH intensity (PRE=24, PERI=24, POST=23). Raw data for 
comparisons between groups in the following columns are presented as mean difference (MD) ± standard error (SE) and 
calculated as PRE-PERI, PRE-POST, and PERI-POST. Statistical significance from ANCOVAs covarying for age is indicated 
by * with corresponding p-values.  
 
































0.76 ± 0.04  0.73 ± 0.06  0.76 ± 0.06 0.03 ± 0.02  0.076 0.00 ± 0.02  0.957 -0.03 ± 0.02  0.603 
Total Test 
Time (sec) 

















0.81 ± 0.10  0.76 ± 0.05  0.82 ± 0.08  
0.046 ± 
0.03  






0.81 ± 0.08  0.83 ± 0.08  0.87 ± 0.12  -0.02 ± 0.03  0.683 -0.06 ± 0.03  0.192 -0.04 ± 0.03  0.252 
RERHIGH 
(a.u.) 
0.92 ± 0.09 0.92 ± 0.08 0.94 ± 0.09 0.00 ± 0.03  0.999 -0.02 ± 0.03 0.999 -0.02 ± 0.03 0.999 
LOWFATox 
(g/min) 
0.20 ± 0.10 0.24 ± 0.06 0.18 ± 0.08 -0.04 ± 0.03 0.999 0.02 ± 0.03 0.558 0.06 ± 0.03 0.051 
MODFATox 
(g/min) 
0.29 ± 0.12 0.24 ± 0.10 0.20 ± 0.11 0.05 ± 0.03 0.129 
0.09 ± 
0.03* 
0.045 0.04 ± 0.03 0.266 
HIGHFATox 
(g/min) 
0.21 ± 0.16 0.15 ± 0.13 0.14 ± 0.13 0.06 ± 0.04 0.999 0.07 ± 0.04 0.999 0.01 ± 0.04 0.999 
LOWCHOox 
(g/min) 
1.09 ± 0.29 1.23 ± 0.20 1.07 ± 0.25 -0.14 ± 0.08 0.999 0.02 ± 0.08 0.999 0.16 ± 0.08 0.152 
MODCHOox 
(g/min) 
1.62 ± 0.34 1.46 ± 0.42 1.34 ± 0.42 0.16 ± 0.11 0.330 0.28 ± 0.12 0.160 0.12 ± 0.12 0.531 
HIGHCHOox 
(g/min) 




















-0.28 ± 3.25 0.999 4.12 ± 3.29 0.999 4.39 ± 3.29 0.999 
ΔRERLOW 0.05 ± 0.11 0.03 ± 0.06 0.07 ± 0.09 0.02 ± 0.03 0.918 -0.15 ± 0.03 0.131 -0.04± 0.03 0.092 






0.040 -0.01± 0.03 0.818 











Table 7. Descriptive statistics for salivary hormones and cardiometabolic blood markers. Data are presented in the PRE, 
PERI, and POST columns as mean ± standard deviation (SD). Raw data for comparisons between groups in the following 
columns are presented as mean difference (MD) ± standard error (SE) and calculated as PRE-PERI, PRE-POST, and 
PERI-POST. Reported p-values were derived from ANCOVAs covaried for age. 




































































































































































Table 8. Descriptive statistics for survey outcomes. Data are presented in the PRE, PERI, and POST columns as mean ± 
standard deviation (SD). Raw data for comparisons between groups in the following columns are presented as mean difference 
(MD) ± standard error (SE) and calculated as PRE-PERI, PRE-POST, and PERI-POST. Number of participants per group is 24 
except for Sitting Time (PRE=20, PERI=18, POST=20); 14 responses were excluded due to ‘not sure’ responses. Statistical 
significance from ANCOVAs covaried for age is indicated by * with corresponding p-values while ANCOVAs covaried for age, 
estradiol, and progesterone (p<0.05) is indicated by † with corresponding p-values. Reported p-values are from ANCOVAs 
covarying for age unless significance was retained following further covariation for estradiol and progesterone. 


















































1.33 ± 1.40 1.08 ± 1.70 1.13 ± 1.45 0.25 ± 0.44 0.999 0.21 ± 0.44 0.999 -0.04 ± 0.44 0.999 
PSQI          
Sleep Quality 
Global Score 
5.08 ± 2.84 6.33 ± 2.91 6.29 ± 3.14 -1.25 ± 0.86 0.999 -1.21 ± 0.86 0.999 0.04 ± 0.86 0.999 




























































































-1.39 ± 1.63 0.999 0.36 ± 1.63 0.999 1.75 ± 1.63 0.999 
NAMS 
Questionnaire 














0.044 2.00 ± 1.52 0.999 
Number of 
Pregnancies 


































Table 9. Distribution of the top 10 reported symptoms. Data are reported as a percentage of each group (n=24 per 
group). 0= ‘Not at all’, 1= ‘A little bit’, 2= ‘Quite a bit’, and 3= “Extremely.” 
 PRE PERI POST  PRE PERI POST 
‘I have hot flashes’    ‘I have headaches’    
0 100% 45% 33% 0 46% 25% 63% 
1 - 33% 54% 1 33% 54% 29% 
2 - 21% 8% 2 17% 21% 8% 
3 - - 4% 3 4% - - 
‘I have night 
sweats’ 
   ‘My vagina is dry’    
0 79% 25% 46% 0 100% 50% 25% 
1 21% 38% 42% 1 - 50% 42% 
2 - 38% 8% 2 - - 21% 
3 - - 4% 3 - - 13% 
‘I feel more tired 
than usual’ 
   
‘I lack desire or interest in 
sexual activity’ 
   
0 63% 21% 46% 0 63% 21% 33% 
1 29% 50% 42% 1 25% 50% 33% 
2 8% 29% 8% 2 13% 21% 25% 
3 - - 4% 3 - 8% 8% 
‘I am more irritable 
than usual’ 
   
‘My stomach feels like it’s 
bloated or I’ve gained weight’ 
   
0 42% 42% 71% 0 54% 21% 25% 
1 46% 46% 21% 1 33% 25% 38% 
2 4% 13% 8% 2 13% 46% 17% 
3 4% - - 3 0% 8% 21% 
‘I have difficulty 
concentrating’ 
   ‘I have joint pains’    
0 50% 25% 46% 0 75% 29% 25% 
1 38% 58% 42% 1 13% 29% 67% 
2 13% 17% 4% 2 13% 38% 4% 






Figure 1. Overview of the menopause transition, estrogen level, and disease risk. Adapted from 
data presented in Chen et al. (2019)2, Greendale et al. (2012)84, Greendale et al. (2019)142, 



























Figure 3. Body fat percentage derived from the 4C model per group. Statistical significance 
(p<0.05) from the ANCOVA covaried for age, estradiol, and progesterone between PRE and 

























Figure 4. Android to gynoid ratio derived from DXA per group. Statistical significance (p<0.05) 
from the ANCOVA covaried for age, estradiol, and progesterone between PRE and PERI is 






















































































































































































Figure 11. Box-and-whisker plots for number of menopause symptoms and sleep quality per 
group. Statistical significance (p<0.05) from an ANCOVA covaried for age is indicated by *, 
while significance (p<0.05) retained from an ANCOVA covaried for age, estradiol, and 




























Muscle Characteristics  
It is important to understand how muscle characteristics change through the menopause 
transition as muscle size and function are directly related to quality of life and chronic disease. In 
the present study, mCSA decreased in a stepwise fashion, with an average 1.50 cm2 decrease 
from PRE to PERI and PERI to POST, respectively. Interestingly, EI increased largely from PRE 
to PERI (MD 17.76 a.u.) and remained high in POST, indicating a nonlinear reduction in muscle 
quality (i.e., increased non-contractile tissue infiltration) incited by peri-menopause followed by 
stabilization in post-menopause. Despite the fact that these comparisons did not reach statistical 
significance, the MD of 17.76 a.u. observed from PRE to PERI greatly surpasses the SEM (0.41 
a.u), indicating clinical significance. Previous data using specific muscle force (i.e., maximum 
voluntary force generated per CSA) as a measure of muscle quality, identified a dramatic decline 
in menopause-aged women (~55 yrs) that was not observed in men19. This group also noted that 
women using hormone replacement therapy did not experience the same reduction in specific 
force, indicating potential roles of hormones and menopause on maintain muscle quality17,19. 
Another study identified that while aging was associated with reduction in strength, mCSA only 
accounted for about 39% of this reduction; data from the present study supports that muscle 
quality may also be a contributing factor to reduced strength74. Because FM gain through the 
menopause transition is common, and lower muscle quality (greater fat and fiber infiltration) is 
associated with reduced whole-muscle force production, it is not surprising that menopause 
exacerbates the reduction of  muscle quality associated with aging alone75,76,142. Together, 




observed during late peri-menopause18, highlight the menopause transition as a crucial window 
for intervention.   
Cardiometabolic Blood Markers 
Being post-menopausal is associated with a 60% increased risk of MetS, which is 
characterized by increased VAT, elevated TC, reduced HDL, and elevated LDL and is likely 
associated with changes in body composition during and after the menopause transition4,13. We 
observed an upward linear trend in TC, with POST average being over 200 mg/dL (i.e., 
borderline high181; mean 202.7 mg/dL). A recent meta-analysis that encompassed 66 cross-
sectional studies including lipid profiles through menopause reported an average TC value of 
184.5 mg/dL in PRE, which was nearly identical to the PRE mean reported in the present study 
(mean 184.5 mg/dL), however, their reported value for POST was 215.39 mg/dL, which was 
slightly higher than the values in our POST group182. An upward linear trend was also observed 
for HDL, which was similarly observed in a longitudinal study, however, this longitudinal study 
was able to assess HDL subclasses and identified adverse changes in HDL function defined as 
cholesterol efflux capacity per HDL particle183. The previously mentioned meta-analysis 
demonstrated no significant differences in HDL between PRE and POST, which mirrored the 
absent statistical significance in the present study for HDL despite the upward trend182. Both 
LDL and nHDL demonstrated a linear upward trend in the present study, which was similar to 
the meta-analysis; in the present study, the average LDL values in PRE and POST were 104.6 
mg/dL and 113.9 mg/dL, respectively, which was a lower range than reported in the meta-
analysis (PRE: 112.1 mg/dL; POST: 133.8 mg/dl)182, which may be due to the overall healthy 
nature of the participants in the current study. Regarding TRG, we observed an increase from 




linear upward trend (113.4 mg/dL in PRE to 139.1 in POST)182. Lastly, fasting GLU values were 
similar between all groups, with POST demonstrating the greatest variability. Other studies have 
identified menopause as a time period for decreased insulin sensitivity and increased risk of 
diabetes onset, so it’s possible that the increased physical activity across cohorts reported in 
participants in the present study may have contributed to the consistent glucose (and other lipids) 
values observed184,185. In addition to the overall health of the current study’s participants, there is 
error associated with the Cholestech device (TC, TRG, and HDL was reported to be 6.3-16.2%, 
14.8-30.8%, and 11.5-26.8%, respectively186), which may have also prevented statistically 







1.  Murphy P, Phillips G, Brooks S. Women’s Health Stats & Facts: The American Congress 
of Obstetricians and Gynecologists.; 2011. www.acog.org. Accessed January 24, 2020. 
2.  Chen GC, Arthur R, Iyengar NM, et al. Association between regional body fat and 
cardiovascular disease risk among postmenopausal women with normal body mass index. 
Eur Heart J. 2019;40(34):2849-2855. doi:10.1093/eurheartj/ehz391 
3.  Witteman JC, Grobbee DE, Kok FJ, Hofman A, Valkenburg HA. Increased risk of 
atherosclerosis in women after the menopause. BMJ. 1989;298(6674):642-644. 
doi:10.1136/bmj.298.6674.642 
4.  Park YW, Zhu S, Palaniappan L, Heshka S, Carnethon MR, Heymsfield SB. The 
metabolic syndrome: Prevalence and associated risk factor findings in the US population 
from the Third National Health and Nutrition Examination Survey, 1988-1994. Arch 
Intern Med. 2003;163(4):427-436. doi:10.1001/archinte.163.4.427 
5.  Papageorgiou M, Sathyapalan T, Schutte R. Muscle mass measures and incident 
osteoporosis in a large cohort of postmenopausal women. J Cachexia Sarcopenia Muscle. 
2019;10(1):131-139. doi:10.1002/jcsm.12359 
6.  Nakamura T, Imai Y, Matsumoto T, et al. Estrogen Prevents Bone Loss via Estrogen 
Receptor α and Induction of Fas Ligand in Osteoclasts. Cell. 2007;130(5):811-823. 
doi:10.1016/j.cell.2007.07.025 
7.  Greendale GA, Lee NP, Arriola ER. The menopause. Lancet. 1999;353(9152):571-580. 
doi:10.1016/S0140-6736(98)05352-5 
8.  Van Pelt RE, Gavin KM, Kohrt WM. Regulation of Body Composition and Bioenergetics 
by Estrogens. Endocrinol Metab Clin North Am. 2015;44(3):663-676. 
doi:10.1016/j.ecl.2015.05.011 
9.  Rettberg JR, Yao J, Brinton RD. Estrogen: A master regulator of bioenergetic systems in 
the brain and body. Front Neuroendocrinol. 2014;35(1):8-30. 
doi:10.1016/j.yfrne.2013.08.001 
10.  Piers LS, Soares MJ, McCormack LM, O’Dea K. Is there evidence for an age-related 





11.  Hodson L, Harnden K, Banerjee R, et al. Lower resting and total energy expenditure in 
postmenopausal compared with premenopausal women matched for abdominal obesity. J 
Nutr Sci. 2014;3. doi:10.1017/jns.2013.38 
12.  Lovejoy JC, Champagne CM, De Jonge L, Xie H, Smith SR. Increased visceral fat and 
decreased energy expenditure during the menopausal transition. Int J Obes. 
2008;32(6):949-958. doi:10.1038/ijo.2008.25 
13.  Carr MC. The Emergence of the Metabolic Syndrome with Menopause. J Clin Endocrinol 
Metab. 2003;88(6):2404-2411. doi:10.1210/jc.2003-030242 
14.  Toth MJ, Tchernof A, Sites CK, Poehlman ET. Menopause-Related Changes in Body Fat 
Distribution. Ann N Y Acad Sci. 2006;904(1):502-506. doi:10.1111/j.1749-
6632.2000.tb06506.x 
15.  Greendale GA, Sternfeld B, Huang M, et al. Changes in body composition and weight 
during the menopause transition. JCI insight. 2019;4(5). doi:10.1172/jci.insight.124865 
16.  Benjamin EJ, Muntner P, Alonso A, et al. Heart Disease and Stroke Statistics-2019 
Update: A Report From the American Heart Association. Circulation. 2019;139(10):e56-
e528. doi:10.1161/CIR.0000000000000659 
17.  Lowe DA, Baltgalvis KA, Greising SM. Mechanisms behind estrogen’s beneficial effect 
on muscle strength in females. Exerc Sport Sci Rev. 2010;38(2):61-67. 
doi:10.1097/JES.0b013e3181d496bc 
18.  Park Y-M, Jankowski CM, Ozemek C, Hildreth KL, Kohrt WM, Moreau KL. 
Appendicular lean mass is lower in late- compared to early- perimenopausal women: 
potential role of FSH. J Appl Physiol. April 2020. doi:10.1152/japplphysiol.00315.2019 
19.  Phillips SK, Rook KM, Siddle NC, Bruce SA, Woledge RC. Muscle weakness in women 
occurs at an earlier age than in men, but strength is preserved by hormone replacement 
therapy. Clin Sci. 1993;84(1):95-98. doi:10.1042/cs0840095 
20.  Mozaffarian D, Wilson PWF, Kannel WB. Beyond established and novel risk factors: 
lifestyle risk factors for cardiovascular disease. Circulation. 2008;117(23):3031-3038. 
doi:10.1161/CIRCULATIONAHA.107.738732 




Implications for exercise performance in eumenorrhoeic women. Sport Med. 
2010;40(3):207-227. doi:10.2165/11317090-000000000-00000 
22.  Reilly T. The Menstrual Cycle and Human Performance: An Overview. 
https://doi.org/101076/0929-1016(200002)31:1;1-0;FT029. 2010. doi:10.1076/0929-
1016(200002)31:1;1-0;FT029 
23.  Lebrun CM. The effect of the phase of the menstrual cycle and the birth control pill on 
athletic performance. Clin Sports Med. 1994;13(2):419-441. 
24.  Wetendorf M, DeMayo FJ. Progesterone receptor signaling in the initiation of pregnancy 
and preservation of a healthy uterus. Int J Dev Biol. 2014;58(2-4):95-106. 
doi:10.1387/ijdb.140069mw 
25.  Klein NA, Soules MR. Endocrine changes of the perimenopause. Clin Obstet Gynecol. 
1998;41(4):912-920. doi:10.1097/00003081-199812000-00017 
26.  How Do I Know I’m in Menopause? | The North American Menopause Society, NAMS. 
https://www.menopause.org/for-women/menopauseflashes/menopause-symptoms-and-
treatments/how-do-i-know-i’m-in-menopause-. Accessed March 18, 2020. 
27.  Santoro N, Epperson CN, Mathews SB. Menopausal Symptoms and Their Management. 
Endocrinol Metab Clin North Am. 2015;44(3):497-515. doi:10.1016/j.ecl.2015.05.001 
28.  Randolph JF, Zheng H, Sowers MFR, et al. Change in follicle-stimulating hormone and 
estradiol across the menopausal transition: Effect of age at the final menstrual period. J 
Clin Endocrinol Metab. 2011;96(3):746-754. doi:10.1210/jc.2010-1746 
29.  Metcalf MG, Donald RA, Livesey JH. Pituitary‐Ovarian Function in Normal Women 
During the Menopausal Transition. Clin Endocrinol (Oxf). 1981;14(3):245-255. 
doi:10.1111/j.1365-2265.1981.tb00193.x 
30.  Santoro N, Lasley B, McConnell D, et al. Body size and ethnicity are associated with 
menstrual cycle alterations in women in the early menopausal transition: The Study of 
Women’s Health across the Nation (SWAN) daily hormone study. In: Journal of Clinical 
Endocrinology and Metabolism. Vol 89. ; 2004:2622-2631. doi:10.1210/jc.2003-031578 
31.  El Khoudary SR, Greendale G, Crawford SL, et al. The menopause transition and 




the Nation (SWAN). Menopause. 2019;26(10):1213-1227. 
doi:10.1097/GME.0000000000001424 
32.  Park CJ, Zhao Z, Glidewell-Kenney C, et al. Genetic rescue of nonclassical ERα signaling 
normalizes energy balance in obese Erα-null mutant mice. J Clin Invest. 2011;121(2):604-
612. doi:10.1172/JCI41702 
33.  Ogawa S, Chan J, Gustafsson J-A, Korach KS, Pfaff DW. Estrogen increases locomotor 
activity in mice through estrogen receptor alpha: specificity for the type of activity. 
Endocrinology. 2003;144(1):230-239. doi:10.1210/en.2002-220519 
34.  Isacco L, Duch P, Boisseau N. Influence of hormonal status on substrate utilization at rest 
and during exercise in the female population. Sport Med. 2012;42(4):327-342. 
doi:10.2165/11598900-000000000-00000 
35.  Bisdee JT, James WPT, Shaw MA. Changes in energy expenditure during the menstrual 
cycle. Br J Nutr. 1989;61(2):187-199. doi:10.1079/bjn19890108 
36.  Day DS, Gozansky WS, Van Pelt RE, Schwartz RS, Kohrt WM. Sex Hormone 
Suppression Reduces Resting Energy Expenditure and β-Adrenergic Support of Resting 
Energy Expenditure. J Clin Endocrinol Metab. 2005;90(6):3312-3317. 
doi:10.1210/jc.2004-1344 
37.  Melanson EL, Gavin KM, Shea KL, et al. Regulation of energy expenditure by estradiol in 
premenopausal women. J Appl Physiol. 2015;119(9):975-981. 
doi:10.1152/japplphysiol.00473.2015 
38.  Duval K, Prud’homme D, Rabasa-Lhoret R, et al. Effects of the menopausal transition on 
energy expenditure: a MONET Group Study.[Erratum appears in Eur J Clin Nutr. 2014 
Jan;68(1):142]. Eur J Clin Nutr. 2013;67(4):407-411. 
http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med
l&AN=23422924. Accessed April 10, 2020. 
39.  Ravussin E, Bogardus C. Relationship of genetics, age, and physical fitness to daily 
energy expenditure and fuel utilization. Am J Clin Nutr. 1989;49(5 SUPPL.):968-975. 
doi:10.1093/ajcn/49.5.968 
40.  Gallagher D, Visser M, Wang Z, Harris T, Pierson RN, Heymsfield SB. Metabolically 
active component of fat-free body mass: influences of age, adiposity, and gender. 




41.  Poehlman ET, Goran MI, Gardner AW, et al. Determinants of decline in resting metabolic 
rate in aging females. Am J Physiol - Endocrinol Metab. 1993;264(3 27-3). 
doi:10.1152/ajpendo.1993.264.3.e450 
42.  Abildgaard J, Pedersen AT, Green CJ, et al. Menopause is associated with decreased 
whole body fat oxidation during exercise. Am J Physiol - Endocrinol Metab. 
2013;304(11):E1227-36. doi:10.1152/ajpendo.00492.2012 
43.  Goodpaster BH, Sparks LM. Metabolic Flexibility in Health and Disease. Cell Metab. 
2017;25(5):1027-1036. doi:10.1016/j.cmet.2017.04.015 
44.  Van Loon LJC, Jeukendrup AE, Saris WHM, Wagenmakers AJM. Effect of training status 
on fuel selection during submaximal exercise with glucose ingestion. J Appl Physiol. 
1999;87(4):1413-1420. doi:10.1152/jappl.1999.87.4.1413 
45.  Sherman WM, Costill DL, Fink WJ, Miller JM. Effect of exercise-diet manipulation on 
muscle glycogen and its subsequent utilization during performance. Int J Sports Med. 
1981;2(2):114-118. doi:10.1055/s-2008-1034594 
46.  Karlsson J, Saltin B. Diet, muscle glycogen, and endurance performance. J Appl Physiol. 
1971;31(2):203-206. doi:10.1152/jappl.1971.31.2.203 
47.  Jeukendrup AE, Wallis GA. Measurement of substrate oxidation during exercise by means 
of gas exchange measurements. Int J Sport Med Suppl. 2005;26(1). doi:10.1055/s-2004-
830512 
48.  Jensen J, Riits BJ, Hummer L, Christiansen C. The effects of age and body composition 
on circulating serum oestrogens and androstenedione after the menopause. BJOG An Int J 
Obstet Gynaecol. 1985;92(3):260-265. doi:10.1111/j.1471-0528.1985.tb01092.x 
49.  Aloia J, Vaswani A, Ma R, Metabolism EF-, 1996  undefined. Aging in women—the four-
compartment model of body composition. Elsevier. 
https://www.sciencedirect.com/science/article/pii/S0026049596901985. Accessed April 4, 
2020. 
50.  Wildman RP, Sowers MFR. Adiposity and the Menopausal Transition. Obstet Gynecol 
Clin North Am. 2011;38(3):441-454. doi:10.1016/j.ogc.2011.05.003 




male and female estrogen receptor-alpha knockout mice. Proc Natl Acad Sci U S A. 
2000;97(23):12729-12734. doi:10.1073/pnas.97.23.12729 
52.  D’Eon TM, Souza SC, Aronovitz M, Obin MS, Fried SK, Greenberg AS. Estrogen 
regulation of adiposity and fuel partitioning. Evidence of genomic and non-genomic 
regulation of lipogenic and oxidative pathways. J Biol Chem. 2005;280(43):35983-35991. 
doi:10.1074/jbc.M507339200 
53.  Campbell SE, Febbraio MA. Effect of ovarian hormones on mitochondrial enzyme 
activity in the fat oxidation pathway of skeletal muscle. Am J Physiol - Endocrinol Metab. 
2001;281(4 44-4). doi:10.1152/ajpendo.2001.281.4.e803 
54.  Flegal KM, Carroll MD, Ogden CL, Curtin LR. Prevalence and trends in obesity among 
US adults, 1999-2008. JAMA - J Am Med Assoc. 2010;303(3):235-241. 
doi:10.1001/jama.2009.2014 
55.  Svendsen OL, Hassager C, Christiansen C. Age- and menopause-associated variations in 
body composition and fat distribution in healthy women as measured by dual-energy X-
ray absorptiometry. Metabolism. 1995;44(3):369-373. doi:10.1016/0026-0495(95)90168-x 
56.  Lovejoy JC. The menopause and obesity. Prim Care - Clin Off Pract. 2003;30(2):317-
325. doi:10.1016/S0095-4543(03)00012-5 
57.  Toth MJ, Tchernof A, Sites CK, Poehlman ET. Effect of menopausal status on body 
composition and abdominal fat distribution. Int J Obes. 2000;24(2):226-231. 
doi:10.1038/sj.ijo.0801118 
58.  Ambikairajah A, Walsh E, Tabatabaei-Jafari H, Cherbuin N. Fat mass changes during 
menopause: a metaanalysis. Am J Obstet Gynecol. 2019;221(5):393-409.e50. 
doi:10.1016/j.ajog.2019.04.023 
59.  Siervogel RM, Wisemandle W, Maynard LM, et al. Serial Changes in Body Composition 
Throughout Adulthood and Their Relationships to Changes in Lipid and Lipoprotein 
Levels. Arterioscler Thromb Vasc Biol. 1998;18(11):1759-1764. 
doi:10.1161/01.ATV.18.11.1759 
60.  Shuster A, Patlas M, Pinthus JH, Mourtzakis M. The clinical importance of visceral 





61.  Smith-Ryan AE, Blue MNM, Trexler ET, Hirsch KR. Utility of ultrasound for body fat 
assessment: validity and reliability compared to a multicompartment criterion. Clin 
Physiol Funct Imaging. 2018;38(2):220-226. doi:10.1111/cpf.12402 
62.  Janssen I, Powell LH, Kazlauskaite R, Dugan SA. Testosterone and visceral fat in midlife 
women: The study of women’s health across the nation (SWAN) fat patterning study. 
Obesity. 2010;18(3):604-610. doi:10.1038/oby.2009.251 
63.  Whitaker KM, Choh AC, Lee M, Towne B, Czerwinski SA, Demerath EW. Sex 
differences in the rate of abdominal adipose accrual during adulthood: The Fels 
Longitudinal Study. Int J Obes. 2016;40(8):1278-1285. doi:10.1038/ijo.2016.48 
64.  Donato GB, Fuchs SC, Oppermann K, Bastos C, Spritzer PM. Association between 
menopause status and central adiposity measured at different cutoffs of waist 
circumference and waist-to-hip ratio. Menopause. 2006;13(2):280-285. 
doi:10.1097/01.gme.0000177907.32634.ae 
65.  Sternfeld B, Wang H, Quesenberry CP, et al. Physical activity and changes in weight and 
waist circumference in midlife women: findings from the Study of Women’s Health 
Across the Nation. Am J Epidemiol. 2004;160(9):912-922. doi:10.1093/aje/kwh299 
66.  Freeman EW, Sammel MD, Lin H, Gracia CR. Obesity and reproductive hormone levels 
in the transition to menopause. Menopause. 2010;17(4):718-726. 
doi:10.1097/gme.0b013e3181cec85d 
67.  Brown JC, Harhay MO, Harhay MN. Appendicular lean mass and mortality among 
prefrail and frail older adults. J Nutr Heal Aging. 2017;21(3):342-345. 
doi:10.1007/s12603-016-0753-7 
68.  Toss F, Wiklund P, Nordström P, Nordström A. Body composition and mortality risk in 
later life. Age Ageing. 2012;41(5):677-681. doi:10.1093/ageing/afs087 
69.  Lynch NA, Metter EJ, Lindle RS, et al. Muscle quality. I. Age-associated differences 
between arm and leg muscle groups. J Appl Physiol. 1999;86(1):188-194. 
doi:10.1152/jappl.1999.86.1.188 
70.  Rosenberg JG, Ryan ED, Sobolewski EJ, Scharville MJ, Thompson BJ, King GE. 
Reliability of panoramic ultrasound imaging to simultaneously examine muscle size and 





71.  Enns DL, Tiidus PM. The influence of estrogen on skeletal muscle: Sex matters. Sport 
Med. 2010;40(1):41-58. doi:10.2165/11319760-000000000-00000 
72.  Carvalho LP, Borghi-Silva A, Dupontgand S, Di Thommazo-Luporini L, Mendes RG, 
Aubertin-Leheudre M. Influence of menopausal status on the main contributors of muscle 
quality. Climacteric. 2018;21(3):298-302. doi:10.1080/13697137.2018.1428294 
73.  Da Câmara SMA, Zunzunegui MV, Pirkle C, Moreira MA, Maciel ÁCC. Menopausal 
status and physical performance in middle aged women: A cross-sectional community-
based study in Northeast Brazil. PLoS One. 2015;10(3):e0119480. 
doi:10.1371/journal.pone.0119480 
74.  Jubrias SA, Odderson IR, Esselman PC, Conley KE. Decline in isokinetic force with age: 
Muscle cross-sectional area and specific force. Pflugers Arch Eur J Physiol. 
1997;434(3):246-253. doi:10.1007/s004240050392 
75.  Rahemi H, Nigam N, Wakeling JM. The effect of intramuscular fat on skeletal muscle 
mechanics: implications for the elderly and obese. J R Soc Interface. 
2015;12(109):20150365. doi:10.1098/rsif.2015.0365 
76.  Ryan ED, Shea NW, Gerstner GR, Barnette TJ, Tweedell AJ, Kleinberg CR. The 
influence of subcutaneous fat on the relationship between body composition and 
ultrasound-derived muscle quality. Appl Physiol Nutr Metab. 2016;41(10):1104-1107. 
doi:10.1139/apnm-2016-0238 
77.  Wong AK, Chandrakumar A, Whyte R, et al. Bone Marrow and Muscle Fat Infiltration 
Are Correlated among Postmenopausal Women With Osteoporosis: The AMBERS Cohort 
Study. J Bone Miner Res. 2020;35(3):516-527. doi:10.1002/jbmr.3910 
78.  Imai Y, Youn MY, Kondoh S, et al. Estrogens maintain bone mass by regulating 
expression of genes controlling function and life span in mature osteoclasts. Ann N Y Acad 
Sci. 2009;1173(SUPPL. 1). doi:10.1111/j.1749-6632.2009.04954.x 
79.  Graham JD, Clarke CL. Physiological Action of Progesterone in Target Tissues. Endocr 
Rev. 1997;18(4):502-519. doi:10.1210/edrv.18.4.0308 
80.  Beresford JN, Gallagher JA, Poser JW, Russell RGG. Production of osteocalcin by human 
bone cells in vitro. Effects of 1,25(OH)2D3, 24,25(OH)2D3, parathyroid hormone, and 





81.  Chin K-Y. The Relationship between Follicle-stimulating Hormone and Bone Health: 
Alternative Explanation for Bone Loss beyond Oestrogen? Int J Med Sci. 
2018;15(12):1373-1383. doi:10.7150/ijms.26571 
82.  Sowers MFR, Jannausch M, McConnell D, et al. Hormone predictors of bone mineral 
density changes during the menopausal transition. J Clin Endocrinol Metab. 
2006;91(4):1261-1267. doi:10.1210/jc.2005-1836 
83.  Blunt BA, Klauber MR, Barrett-Connor EL, Edelstein SL. Sex differences in bone mineral 
density in 1653 men and women in the sixth through tenth decades of life: the Rancho 
Bernardo Study. J Bone Miner Res. 1994;9(9):1333-1338. doi:10.1002/jbmr.5650090903 
84.  Greendale GA, Sowers M, Han W, et al. Bone mineral density loss in relation to the final 
menstrual period in a multiethnic cohort: Results from the Study of Women’s Health 
Across the Nation (SWAN). J Bone Miner Res. 2012;27(1):111-118. 
doi:10.1002/jbmr.534 
85.  Greendale GA, Huang M, Cauley JA, et al. Trabecular Bone Score Declines During the 
Menopause Transition: The Study of Women’s Health Across the Nation (SWAN). J Clin 
Endocrinol Metab. 2020;105(4). doi:10.1210/clinem/dgz056 
86.  Arem H, Moore SC, Patel A, et al. Leisure time physical activity and mortality: A detailed 
pooled analysis of the dose-response relationship. JAMA Intern Med. 2015;175(6):959-
967. doi:10.1001/jamainternmed.2015.0533 
87.  Melanson EL, Lyden K, Gibbons E, et al. Influence of estradiol status on physical activity 
in premenopausal women. Med Sci Sports Exerc. 2018;50(8):1704-1709. 
doi:10.1249/MSS.0000000000001598 
88.  Moilanen JM, Aalto A-M, Raitanen J, Hemminki E, Aro AR, Luoto R. Physical activity 
and change in quality of life during menopause--an 8-year follow-up study. Health Qual 
Life Outcomes. 2012;10:8. doi:10.1186/1477-7525-10-8 
89.  Pettee Gabriel K, Sternfeld B, Colvin A, et al. Physical activity trajectories during midlife 
and subsequent risk of physical functioning decline in late mid-life: The Study of 
Women’s Health Across the Nation (SWAN). Prev Med (Baltim). 2017;105:287-294. 
doi:10.1016/j.ypmed.2017.10.005 
90.  Geary N, Asarian L, Korach KS, Pfaff DW, Ogawa S. Deficits in E2-dependent control of 





91.  Duval K, Prud’Homme D, Rabasa-Lhoret R, et al. Effects of the menopausal transition on 
dietary intake and appetite: A MONET Group Study. Eur J Clin Nutr. 2014;68(2):271-
276. doi:10.1038/ejcn.2013.171 
92.  Krystal AD, Edinger JD. Measuring sleep quality. Sleep Med. 2008;9(SUPPL. 1). 
doi:10.1016/S1389-9457(08)70011-X 
93.  Buysse DJ, Reynolds CF, Monk TH, Berman SR, Kupfer DJ. The Pittsburgh sleep quality 
index: A new instrument for psychiatric practice and research. Psychiatry Res. 
1989;28(2):193-213. doi:10.1016/0165-1781(89)90047-4 
94.  Branchey M, Branchey L, Nadler RD. Effects of estrogen and progesterone on sleep 
patterns of female rats. Physiol Behav. 1971;6(6):743-746. doi:10.1016/0031-
9384(71)90267-8 
95.  Polo-Kantola P, Erkkola R, Irjala K, Pullinen S, Virtanen I, Polo O. Effect of short-term 
transdermal estrogen replacement therapy on sleep: A randomized, double-blind crossover 
trial in postmenopausal women. Fertil Steril. 1999;71(5):873-880. doi:10.1016/S0015-
0282(99)00062-X 
96.  Zhang JP, Wang YQ, Yan MQ, Li ZA, Du XP, Wu XQ. Menopausal symptoms and sleep 
quality during menopausal transition and postmenopause. Chin Med J (Engl). 
2016;129(7):771-777. doi:10.4103/0366-6999.178961 
97.  Kravitz HM, Zhao X, Bromberger JT, et al. Sleep disturbance during the menopausal 
transition in a multi-ethnic community sample of women. Sleep. 2008;31(7):979-990. 
http://www.ncbi.nlm.nih.gov/pubmed/18652093. Accessed April 19, 2020. 
98.  Baker FC, Lampio L, Saaresranta T, Polo-Kantola P. Sleep and Sleep Disorders in the 
Menopausal Transition. Sleep Med Clin. 2018;13(3):443-456. 
doi:10.1016/j.jsmc.2018.04.011 
99.  Simmons A, Falbe J, Vacek J. Coronary artery disease in women: A review and update. 
Rev Cardiovasc Med. 2011;12(2):84-93. doi:10.3909/ricm0564 
100.  Samargandy S, Matthews KA, Brooks MM, et al. Arterial Stiffness Accelerates Within 1 




Biol. 2020;40(4):1001-1008. doi:10.1161/ATVBAHA.119.313622 
101.  Rhéaume C, Leblanc MV, Poirier P. Adiposity assessment: Explaining the association 
between obesity, hypertension and stroke. Expert Rev Cardiovasc Ther. 2011;9(12):1557-
1564. doi:10.1586/erc.11.167 
102.  Fox CS, Hwang S-J, Massaro JM, et al. Relation of subcutaneous and visceral adipose 
tissue to coronary and abdominal aortic calcium (from the Framingham Heart Study). Am 
J Cardiol. 2009;104(4):543-547. doi:10.1016/j.amjcard.2009.04.019 
103.  Azizi F, Esmaillzadeh A, Mirmiran P, Ainy E. Is there an independent association 
between waist-to-hip ratio and cardiovascular risk factors in overweight and obese 
women? Int J Cardiol. 2005;101(1):39-46. doi:10.1016/j.ijcard.2004.03.011 
104.  Hoffman EL, VonWald T, Hansen K. The metabolic syndrome. S D Med. 2015:24-28. 
doi:10.1210/jcem.89.6.9995 
105.  Alberti KGMM, Eckel RH, Grundy SM, et al. Harmonizing the metabolic syndrome: A 
joint interim statement of the international diabetes federation task force on epidemiology 
and prevention; National heart, lung, and blood institute; American heart association; 
World heart federation; International atherosclerosis society; And international association 
for the study of obesity. Circulation. 2009;120(16):1640-1645. 
doi:10.1161/CIRCULATIONAHA.109.192644 
106.  Grundy SM, Brewer HB, Cleeman JI, Smith SC, Lenfant C. Definition of Metabolic 
Syndrome. Arterioscler Thromb Vasc Biol. 2004;24(2). 
doi:10.1161/01.atv.0000111245.75752.c6 
107.  Kassi E, Pervanidou P, Kaltsas G, Chrousos G. Metabolic syndrome: Definitions and 
controversies. BMC Med. 2011;9(1):1-13. doi:10.1186/1741-7015-9-48 
108.  Ervin RB. Prevalence of metabolic syndrome among adults 20 years of age and over, by 
sex, age, race and ethnicity, and body mass index: United States, 2003-2006. Natl Health 
Stat Report. 2009;(13). 
109.  Jensen J, Nilas L, Christiansen C. Influence of menopause on serum lipids and 
lipoproteins. Maturitas. 1990;12(4):321-331. doi:10.1016/0378-5122(90)90012-u 




changes during the menopause transition in relation to age and weight: the Study of 
Women’s Health Across the Nation. Am J Epidemiol. 2009;169(11):1352-1361. 
doi:10.1093/aje/kwp043 
111.  Randolph JF, Sowers M, Bondarenko I V., Harlow SD, Luborsky JL, Little RJ. Change in 
estradiol and follicle-stimulating hormone across the early menopausal transition: Effects 
of ethnicity and age. J Clin Endocrinol Metab. 2004;89(4):1555-1561. 
doi:10.1210/jc.2003-031183 
112.  Glaser DL, Kaplan FS. Osteoporosis: Definition and clinical presentation. Spine (Phila Pa 
1976). 1997;22(24 SUPPL.). doi:10.1097/00007632-199712151-00003 
113.  Karlamangla AS, Burnett-Bowie SAM, Crandall CJ. Bone Health During the Menopause 
Transition and Beyond. Obstet Gynecol Clin North Am. 2018;45(4):695-708. 
doi:10.1016/j.ogc.2018.07.012 
114.  Prakash M, Stojanovska L, Nurgali K, Apostolopoulos V. Exercise in Menopausal 
Women. In: Hackney AC, ed. Sex Hormones, Exercise and Women. Springer International 
Publishing; 2017:285-300. 
115.  Daley A, Macarthur C, Stokes-Lampard H, McManus R, Wilson S, Mutrie N. Exercise 
participation, body mass index, and health-related quality of life in women of menopausal 
age. Br J Gen Pract. 2007;57(535):130-135. 
http://www.ncbi.nlm.nih.gov/pubmed/17266830. Accessed April 25, 2020. 
116.  Daley A, Stokes-Lampard H, Wilson S, Rees M, Roalfe A, MacArthur C. What women 
want? Exercise preferences of menopausal women. Maturitas. 2011;68(2):174-178. 
doi:10.1016/j.maturitas.2010.11.011 
117.  McMurray RG, Ainsworth BE, Harrell JS, Griggs TR, Williams OD. Is physical activity 
or aerobic power more influential on reducing cardiovascular disease risk factors? Med Sci 
Sports Exerc. 1998;30(10):1521-1529. doi:10.1097/00005768-199810000-00009 
118.  Chlebowski RT. Nutrition and physical activity influence on breast cancer incidence and 
outcome. Breast. 2013;22(S2). doi:10.1016/j.breast.2013.07.006 
119.  Seo D il, So WY, Ha S, et al. Effects of 12 weeks of combined exercise training on 





120.  Gelecek N, Ilçin N, Subaşi SS, Acar S, Demir N, Örmen M. The Effects of Resistance 
Training on Cardiovascular Disease Risk Factors in Postmenopausal Women: A 
Randomized-Controlled Trial. Health Care Women Int. 2012;33(12):1072-1085. 
doi:10.1080/07399332.2011.645960 
121.  Hunter SD, Dhindsa M, Cunningham E, Tarumi T, Alkatan M, Tanaka H. Improvements 
in glucose tolerance with Bikram yoga in older obese adults: A pilot study. J Bodyw Mov 
Ther. 2013;17(4):404-407. doi:10.1016/j.jbmt.2013.01.002 
122.  Gao HL, Gao HX, Sun FM, Zhang L. Effects of walking on body composition in 
perimenopausal and postmenopausal women: A systematic review and meta-analysis. 
Menopause. 2016;23(8):928-934. doi:10.1097/GME.0000000000000627 
123.  Boutcher YN, Boutcher SH, Yoo HY, Meerkin JD. The Effect of Sprint Interval Training 
on Body Composition of Postmenopausal Women. Med Sci Sports Exerc. 
2019;51(7):1413-1419. doi:10.1249/MSS.0000000000001919 
124.  Kemmler W, Weineck J, Kalender WA, Engelke K. The effect of habitual physical 
activity, non-athletic exercise, muscle strength, and VO2max on bone mineral density is 
rather low in early postmenopausal osteopenic women. J Musculoskelet Neuronal 
Interact. 2004;4(3):325-334. http://www.ncbi.nlm.nih.gov/pubmed/15615501. Accessed 
April 25, 2020. 
125.  Ma D, Wu L, He Z. Effects of walking on the preservation of bone mineral density in 
perimenopausal and postmenopausal women: a systematic review and meta-analysis. 
Menopause. 2013;20(11):1216-1226. doi:10.1097/GME.0000000000000100 
126.  Villareal DT, Steger-May K, Schechtman KB, et al. Effects of exercise training on bone 
mineral density in frail order women and men: A radomised controlled trial. Age Ageing. 
2004;33(3):309-312. doi:10.1093/ageing/afh044 
127.  Zhao R, Zhao M, Xu Z. The effects of differing resistance training modes on the 
preservation of bone mineral density in postmenopausal women: a meta-analysis. 
Osteoporos Int. 2015;26(5):1605-1618. doi:10.1007/s00198-015-3034-0 
128.  Wang ZM, Xavier Pi-Sunyer F, Kotler DP, et al. Multicomponent methods: Evaluation of 
new and traditional soft tissue mineral models by in vivo neutron activation analysis. Am J 
Clin Nutr. 2002;76(5):968-974. doi:10.1093/ajcn/76.5.968 




ultrasound and computerized tomography. Int J Obes. 1993;17(4):209-214. 
130.  Tinsley GM, Morales E, Forsse JS, Grandjean PW. Impact of acute dietary manipulations 
on DXA and BIA body composition estimates. Med Sci Sports Exerc. 2017;49(4):823-
832. doi:10.1249/MSS.0000000000001148 
131.  Nana A, Slater GJ, Hopkins WG, Burke LM. Effects of exercise sessions on DXA 
measurements of body composition in active people. Med Sci Sports Exerc. 
2013;45(1):178-185. doi:10.1249/MSS.0b013e31826c9cfd 
132.  Young H, Jenkins NT, Zhao Q, Mccully KK. Measurementof Intramuscular Fat by 
Muscle Echo Intensity. Muscle and Nerve. 2016;52(6):963-971. 
doi:10.1002/mus.24656.Measurement 
133.  Geneva. Waist Circumference and Waist-Hip Ratio: Report of a WHO Expert 
Consultation. www.who.int. Accessed May 2, 2020. 
134.  Weir JB d. V. New methods for calculating metabolic rate with special reference to 
protein metabolism. J Physiol. 1949;109(1-2):1-9. doi:10.1113/jphysiol.1949.sp004363 
135.  Péronnet F, Massicotte D. Table of nonprotein respiratory quotient: an update. Can J 
Sport Sci. 1991;16(1):23-29. 
136.  Pourhassan M, Eggeling B, Schautz B, et al. Relationship between submaximal oxygen 
uptake, detailed body composition, and resting energy expenditure in overweight subjects. 
Am J Hum Biol. 2015;27(3):397-406. doi:10.1002/ajhb.22666 
137.  Karvonen MJ, Kentala E, Mustala O. The effects of training on heart rate; a longitudinal 
study. Ann Med Exp Biol Fenn. 1957;35(3):307-315. 
138.  Craig CL, Marshall AL, Sjöström M, et al. International physical activity questionnaire: 
12-Country reliability and validity. Med Sci Sports Exerc. 2003;35(8):1381-1395. 
doi:10.1249/01.MSS.0000078924.61453.FB 
139.  Diet History Questionnaire, Version 1.0. 2007. 
https://epi.grants.cancer.gov/dhq/about/citations.html. Accessed May 3, 2020. 




141.  Hale GE, Zhao X, Hughes CL, Burger HG, Robertson DM, Fraser IS. Endocrine features 
of menstrual cycles in middle and late reproductive age and the menopausal transition 
classified according to the Staging of Reproductive Aging Workshop (STRAW) staging 
system. J Clin Endocrinol Metab. 2007;92(8):3060-3067. doi:10.1210/jc.2007-0066 
142.  Greendale GA, Sternfeld B, Huang MH, et al. Changes in body composition and weight 
during the menopause transition. JCI Insight. 2019;4(5). doi:10.1172/jci.insight.124865 
143.  Assaf AR, Bushmakin AG, Joyce N, Louie MJ, Flores M, Moffatt M. The relative burden 
of menopausal and postmenopausal symptoms versus other major conditions: A 
retrospective analysis of the medical expenditure panel survey data. Am Heal Drug 
Benefits. 2017;10(6):311-320. /pmc/articles/PMC5620512/. Accessed March 5, 2021. 
144.  Avis NE, Crawford SL, Greendale G, et al. Duration of menopausal vasomotor symptoms 
over the menopause transition. JAMA Intern Med. 2015;175(4):531-539. 
doi:10.1001/jamainternmed.2014.8063 
145.  Ahlborg HG, Johnell O, Nilsson BE, Jeppsson S, Rannevik G, Karlsson MK. Bone loss in 
relation to menopause: A prospective study during 16 years. Bone. 2001;28(3):327-331. 
doi:10.1016/S8756-3282(00)00451-8 
146.  Bisdee JT, Garlick PJ, James WPT. Metabolic changes during the menstrual cycle. Br J 
Nutr. 1989;61(3):641-650. doi:10.1079/bjn19890151 
147.  North American Menopause Society T. Menopause Health Questionnaire. Pepper Pike, 
Ohio; 2021. https://www.menopause.org/publications/clinical-practice-
materials/menopause-health-questionnaire. Accessed February 4, 2021. 
148.  Buendia R, Seoane F, Lindecrantz K, et al. Estimation of body fluids with bioimpedance 
spectroscopy: state of the art methods  and proposal of novel methods. Physiol Meas. 
2015;36(10):2171-2187. doi:10.1088/0967-3334/36/10/2171 
149.  Moon JR, Tobkin SE, Roberts MD, et al. Total body water estimations in healthy men and 
women using bioimpedance  spectroscopy: a deuterium oxide comparison. Nutr Metab 
(Lond). 2008;5:7. doi:10.1186/1743-7075-5-7 
150.  Smith-Ryan AE, Mock MG, Ryan ED, Gerstner GR, Trexler ET, Hirsch KR. Validity and 
reliability of a 4-compartment body composition model using dual energy x-ray 





151.  Mccrory MA, Molé PA, Gomez TD, Dewey KG, Bernauer EM. Body composition by air-
displacement plethysmography by using predicted and measured thoracic gas volumes. J 
Appl Physiol. 1998;84(4):1475-1479. doi:10.1152/jappl.1998.84.4.1475 
152.  Demerath EW, Guo SS, Chumlea WC, Towne B, Roche AF, Siervogel RM. Comparison 
of percent body fat estimates using air displacement plethysmography and 
hydrodensitometry in adults and children. Int J Obes. 2002;26(3):389-397. 
doi:10.1038/sj.ijo.0801898 
153.  Leite CC, Wajchenberg BL, Radominski R, Matsuda D, Cerri GG, Halpern A. Intra-
abdominal thickness by ultrasonography to predict risk factors for cardiovascular disease 
and its correlation with anthropometric measurements. Metabolism. 2002;51(8):1034-
1040. doi:10.1053/meta.2002.34035 
154.  Stoner L, Chinn V, Cornwall J, et al. Reliability tests and guidelines for B-mode 
ultrasound assessment of central adiposity. Eur J Clin Invest. 2015;45(11):1200-1208. 
doi:10.1111/eci.12540 
155.  Smith-Ryan AE, Hirsch KR, Blue MNM, Mock MG, Trexler ET. High-fat breakfast meal 
replacement in overweight and obesity: Implications on body composition, metabolic 
markers, and satiety. Nutrients. 2019;11(4). doi:10.3390/nu11040865 
156.  Moon JJ, Park S-G, Ryu SM, Park C-H. New Skeletal Muscle Mass Index in Diagnosis of 
Sarcopenia. J Bone Metab. 2018;25(1):15. doi:10.11005/jbm.2018.25.1.15 
157.  Harlow SD, Gass M, Hall JE, et al. Executive summary of the stages of reproductive 
aging workshop + 10: Addressing the unfinished agenda of staging reproductive aging. In: 
Journal of Clinical Endocrinology and Metabolism. Vol 97. J Clin Endocrinol Metab; 
2012:1159-1168. doi:10.1210/jc.2011-3362 
158.  Svendsen OL, Hassager C, Christiansen C. Age- and menopause-associated variations in 
body composition and fat distribution in healthy women as measured by dual-energy x-ray 
absorptiometry. Metabolism. 1995;44(3):369-373. doi:10.1016/0026-0495(95)90168-X 
159.  Visser M, Gallagher D, Deurenberg P, Wang J, Pierson RN, Heymsfield SB. Density of 
fat-free body mass: Relationship with race, age, and level of body fatness. Am J Physiol - 
Endocrinol Metab. 1997;272(5 35-5). doi:10.1152/ajpendo.1997.272.5.e781 
160.  Maltais ML, Desroches J, Dionne IJ. Changes in muscle mass and strength after 




https://pubmed.ncbi.nlm.nih.gov/19949277/. Accessed March 16, 2021. 
161.  Stachenfeld NS. Hormonal changes during menopause and the impact on fluid regulation. 
Reprod Sci. 2014;21(5):555-561. doi:10.1177/1933719113518992 
162.  Blunt BA, Klauber MR, Barrett‐Connor EL, Edelstein SL. Sex differences in bone mineral 
density in 1653 men and women in the sixth through tenth decades of life: The rancho 
bernardo study. J Bone Miner Res. 1994;9(9):1333-1338. doi:10.1002/jbmr.5650090903 
163.  Segev D, Hellerstein D, Dunsky A. Physical Activity-does it Really Increase Bone 
Density in Postmenopausal Women? A Review of Articles Published Between 2001-2016. 
Curr Aging Sci. 2018;11(1):4-9. doi:10.2174/1874609810666170918170744 
164.  Gilliat-Wimberly M, Manore MM, Woolf K, Swan PD, Carroll SS. Effects of habitual 
physical activity on the resting metabolic rates and body compositions of women aged 35 
to 50 years. J Am Diet Assoc. 2001;101(10):1181-1188. doi:10.1016/S0002-
8223(01)00289-9 
165.  Szafran H, Smielak-Korombel W. The role of estrogens in hormonal regulation of lipid 
metabolism in women. Przegla̧d Lek. 1998;55(5):266-270. 
https://europepmc.org/article/med/9741194. Accessed March 11, 2021. 
166.  Suh SH, Casazza GA, Horning MA, Miller BF, Brooks GA. Effects of oral contraceptives 
on glucose flux and substrate oxidation rates during rest and exercise. J Appl Physiol. 
2003;94(1):285-294. doi:10.1152/japplphysiol.00693.2002 
167.  Gould LM, Cabre HE, Brewer GJ, Hirsch KR, Blue MNM, Smith-Ryan AE. Impact of 
Follicular Menstrual Phase on Body Composition Measures and Resting Metabolism. Rev. 
2021. 
168.  Blaak EE, Saris WHM. Substrate oxidation, obesity and exercise training. Best Pract Res 
Clin Endocrinol Metab. 2002;16(4):667-678. doi:10.1053/beem.2002.0226 
169.  Egan B, Zierath JR. Exercise metabolism and the molecular regulation of skeletal muscle 
adaptation. Cell Metab. 2013;17(2):162-184. doi:10.1016/j.cmet.2012.12.012 
170.  Matsuo T, Suzuki M. Effects of dietary composition and exercise timing on substrate 





171.  Gordon JL, Peltier A, Grummisch JA, Sykes Tottenham L. Estradiol fluctuation, 
sensitivity to stress, and depressive symptoms in the menopause transition: A pilot study. 
Front Psychol. 2019;10(JUN). doi:10.3389/fpsyg.2019.01319 
172.  Santoro N. The menopausal transition. In: American Journal of Medicine. Vol 118. 
Elsevier Inc.; 2005:8-13. doi:10.1016/j.amjmed.2005.09.008 
173.  Shideler SE, DeVane GW, Kalra PS, Benirschke K, Lasley BL. Ovarian-pituitary 
hormone interactions during the perimenopause. Maturitas. 1989;11(4):331-339. 
doi:10.1016/0378-5122(89)90029-7 
174.  Ellison PT. Measurements of Salivary Progesterone. Ann N Y Acad Sci. 1993;694(1):161-
175. doi:10.1111/j.1749-6632.1993.tb18350.x 
175.  Meyer J, McDowell C, Lansing J, et al. Changes in physical activity and sedentary 
behavior in response to covid-19 and their associations with mental health in 3052 us 
adults. Int J Environ Res Public Health. 2020;17(18):1-13. doi:10.3390/ijerph17186469 
176.  Liu X, Tang M, Hu L. Reliability and validity of the Pittsburgh sleep quality index. 
Chinese J psychiatry. 1996. 
177.  Subar AF, Kipnis V, Troiano RP, et al. Using intake biomarkers to evaluate the extent of 
dietary misreporting in a large sample of adults: The OPEN study. Am J Epidemiol. 
2003;158(1):1-13. doi:10.1093/aje/kwg092 
178.  Thurston RC, Joffe H. Vasomotor Symptoms and Menopause: Findings from the Study of 
Women’s Health across the Nation. Obstet Gynecol Clin North Am. 2011;38(3):489-501. 
doi:10.1016/j.ogc.2011.05.006 
179.  Weismiller DG. Menopause. Prim Care - Clin Off Pract. 2009;36(1):199-226. 
doi:10.1016/j.pop.2008.10.007 
180.  Dupuit M, Maillard F, Pereira B, Marquezi ML, Lancha AH, Boisseau N. Effect of high 
intensity interval training on body composition in women before and after menopause: a 
meta-analysis. Exp Physiol. 2020;105(9):1470-1490. doi:10.1113/EP088654 





182.  Ambikairajah A, Walsh E, Cherbuin N. Lipid profile differences during menopause: A 
review with meta-analysis. Menopause. 2019;26(11):1327-1333. 
doi:10.1097/GME.0000000000001403 
183.  El Khoudary SR, Chen X, Nasr A, et al. HDL (High-Density Lipoprotein) Subclasses, 
Lipid Content, and Function Trajectories Across the Menopause Transition: SWAN-HDL 
Study. Arterioscler Thromb Vasc Biol. 2020;41(2):ATVBAHA120315355. 
doi:10.1161/ATVBAHA.120.315355 
184.  Otsuki M, Kasayama S, Morita S, et al. Menopause, but not age, is an independent risk 
factor for fasting plasma glucose levels in nondiabetic women. Menopause. 
2007;14(3):404-407. doi:10.1097/01.gme.0000247014.56254.12 
185.  Wen JB, Yang S, Zhao XH, et al. Effect of menopausal status on onset of impaired fasting 
glucose and type 2 diabetes mellitus. Chinese J Prev Med. 2017;51(8):728-733. 
doi:10.3760/cma.j.issn.0253-9624.2017.08.013 
186.  Bard RL, Kaminsky LA, Whaley MH, Zajakowski S. Evaluation of lipid profile 
measurements obtained from the cholestech L·D·X analyzer. J Cardiopulm Rehabil. 
1997;17(6):413-418. doi:10.1097/00008483-199711000-00005 
 
